Skip to content
← All treatment topics

TREATMENT READING

Wilms Tumor and Other Childhood Kidney Tumors

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

97 sections
  1. Treatment of adults with Wilms tumor
  2. Treatment of Wilms Tumor
  3. Treatment option overview for Wilms tumor
  4. COG and SIOP approaches to Wilms tumor treatment
  5. Surgery
  6. Lymph node sampling
  7. Pleural effusions
  8. Chemotherapy
  9. Radiation therapy
  10. COG approach
  11. SIOP approach
  12. Treatment of stage I Wilms tumor
  13. Treatment of stage II Wilms tumor
  14. Treatment of stage II patients with intraoperative spill
  15. Treatment of stage III Wilms tumor
  16. Radiation therapy
  17. Loss of heterozygosity of 1p or 16q
  18. Loss of heterozygosity of 1p and 16q
  19. Treatment of stage IV Wilms tumor
  20. Chromosome 1q gain
  21. Treatment of pulmonary nodules and metastases
  22. Liver metastases at diagnosis
  23. NWTS
  24. SIOP
  25. Treatment of stage IV diffuse anaplastic Wilms tumor
  26. Treatment options under clinical evaluation
  27. Treatment of stage V Wilms tumor and those predisposed to developing bilateral Wilms tumor
  28. Preoperative chemotherapy and resection
  29. Treatment of patients with multicentric or bilaterally predisposed unilateral Wilms tumors
  30. WAGR syndrome and Wilms tumor outcomes
  31. Renal transplant
  32. Treatment options under clinical evaluation
  33. Treatment and outcomes of recurrent Wilms tumor
  34. Prognosis, prognostic factors, and risk categories for recurrent Wilms tumor
  35. Treatment of standard-risk relapsed Wilms tumor
  36. Surgery, radiation therapy, and chemotherapy
  37. Treatment of high-risk and very high-risk relapsed Wilms tumor
  38. Chemotherapy, surgery, and/or radiation therapy
  39. HSCT
  40. Treatment options under clinical evaluation for recurrent Wilms tumor
  41. Follow-up after treatment
  42. Late effects after Wilms tumor therapy
  43. Treatment of RCC
  44. Radical nephrectomy with lymph node sampling
  45. Renal-sparing surgery with lymph node sampling
  46. Other approaches
  47. Treatment Options Under Clinical Evaluation for RCC
  48. Treatment of Rhabdoid Tumor of the Kidney
  49. Treatment Options Under Clinical Evaluation for Rhabdoid Tumors of the Kidney
  50. Treatment of Clear Cell Sarcoma of the Kidney
  51. Surgery, chemotherapy, and radiation therapy
  52. Treatment of Recurrent Clear Cell Sarcoma of the Kidney
  53. Treatment options under clinical evaluation for recurrent clear cell sarcoma of the kidney
  54. Treatment of Congenital Mesoblastic Nephroma
  55. Nephrectomy
  56. Adjuvant chemotherapy
  57. Treatment Options Under Clinical Evaluation for Congenital Mesoblastic Nephroma
  58. Treatment of Recurrent Congenital Mesoblastic Nephroma
  59. Treatment options under clinical evaluation for recurrent congenital mesoblastic nephroma
  60. Treatment of Ewing Sarcoma of the Kidney
  61. Treatment of Primary Renal Myoepithelial Carcinoma
  62. Treatment of Cystic Partially Differentiated Nephroblastoma
  63. Treatment of Multilocular Cystic Nephroma
  64. Treatment of Anaplastic Sarcoma of the Kidney
  65. Treatment of Primary Renal Synovial Sarcoma
  66. Treatment of Nephroblastomatosis (Diffuse Hyperplastic Perilobar Nephroblastomatosis)
  67. Special Considerations for the Treatment of Children With Cancer
  68. Treatment of RCC
  69. Treatment of rhabdoid tumor of the kidney
  70. Types of treatment for kidney cancer in children
  71. Who treats children with kidney cancer?
  72. Treatment options
  73. Surgery
  74. Radiation therapy
  75. Chemotherapy
  76. Immunotherapy
  77. Stem cell transplant
  78. Targeted therapy
  79. Clinical trials
  80. Side effects and late effects of treatment
  81. Types of treatment for Wilms tumor
  82. Who treats children with Wilms tumor?
  83. Treatment options
  84. Surgery
  85. Radiation therapy
  86. Chemotherapy
  87. Stem cell transplant
  88. Clinical trials
  89. Treatment of Wilms tumor by stage and histology
  90. Stage I Wilms tumor
  91. Stage II Wilms tumor
  92. Stage III Wilms tumor
  93. Stage IV Wilms tumor
  94. Stage V Wilms tumor and children at high risk of developing bilateral Wilms tumor
  95. Treatment of cystic partially differentiated nephroblastoma
  96. Treatment of recurrent Wilms tumor
  97. Side effects and late effects of treatment

Health professional · Wilms Tumor / Older Adolescents and Adults With Wilms Tumor

Treatment of adults with Wilms tumor

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

As Wilms tumor rarely occurs in adults, there is no standard treatment protocol. Better results have been reported for adults when they are treated in pediatric trials.

A Wilms tumor in an adult represents a therapeutic emergency because of the tumor's rapid growth and because urologists and oncologists are more familiar with the indolent growth of renal cell carcinoma.

The NWTS Group reported the outcomes for adult patients with Wilms tumor from the NWTS-1, -2, and -3 trials.[195-197]

Sources: 195 · 197

The 3-year OS rate for adults on the NWTS-1 trial was 24% (compared with 74% in children) and improved to a 5-year OS rate of 82.6% on the NWTS-3 trial, although the number of adult patients treated on each trial was 31 or fewer.

These data suggest that many adults with Wilms tumor, if treated appropriately, can expect to be cured, especially if the tumor has not spread and/or is completely resected.

For adults with refractory or recurrent disease, screening for potential therapeutic targets in the tumor should be considered.[198]

Sources: 198

The following recommendations from the renal tumor committees of the International Society of Paediatric Oncology (SIOP) and COG encourage a uniform approach to improve outcome for adults with Wilms tumor.[199]

Sources: 199

Consult with a pediatric oncologist who has experience with the treatment of Wilms tumor as soon as a histological diagnosis is suspected.

Avoid delaying the start of chemotherapy. Ideally, chemotherapy, and radiation therapy if necessary, should be started by day 14 postnephrectomy, although delaying the start until day 30 is acceptable.

Be alert for toxicity of vincristine (neurotoxicity) and dactinomycin (hepatic toxicity) in adults.

Register patients in pediatric renal tumor trials if studies are available and the patients are eligible.

In a series of 14 adult Wilms tumors that were evaluated by expanded targeted sequencing, 5 (36%) demonstrated BRAF V600E variants. These tumors contained areas that were morphologically identical to BRAF V600E–altered metanephric adenoma. All of the BRAF V600E–altered Wilms tumors in this cohort occurred in patients older than 30 years. Identifying a BRAF V600E variant has therapeutic significance because these patients may respond to therapy with BRAF/MEK inhibitors.[136] There was one report of a male (aged 51 years) who had a relapsed metastatic Wilms tumor that harbored a BRAF V600E variant. The patient was treated with the BRAF inhibitor dabrafenib, and they had a prolonged and dramatic response.[198]

Sources: 136 · 198

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Wilms Tumor

Treatment of Wilms Tumor

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Health professional · Wilms Tumor / Treatment of Wilms Tumor

Treatment option overview for Wilms tumor

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Because of the relative rarity of Wilms tumor, all patients with this tumor should consider joining a clinical trial. Treatment planning by a multidisciplinary team of pediatric cancer specialists (surgeon and/or urologist, radiation oncologist, and oncologist) who have experience treating children with Wilms tumor is necessary to determine and implement optimal treatment.

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment option overview for Wilms tumor

COG and SIOP approaches to Wilms tumor treatment

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Most randomized clinical studies for treatment of children with Wilms tumor have been conducted by two large clinical groups (COG RTC and SIOP). Differences between the two groups affect staging and classification. There are two standard approaches to Wilms tumor treatment: the COG RTC uses immediate surgery for all unilateral tumors, and the SIOP uses preoperative chemotherapy as the first step in treatment. Both groups use postoperative chemotherapy, except for selected cases who do not receive chemotherapy, and in advanced stages, radiation therapy is used in a risk-adapted approach.

COG RTC (includes the previous NWTS group): The NWTS group established standard treatment for Wilms tumor in North America, consisting of initial nephrectomy (when feasible) followed by chemotherapy and, in some patients, radiation therapy.[219-221] This approach allows for early and accurate histological diagnosis, collection of biological materials unaltered by therapy, and staging information, such as the presence of tumor spill or tumor involvement in lymph nodes, before chemotherapy is administered.

Sources: 219 · 221

SIOP: SIOP is a European consortium whose trials provide preoperative chemotherapy before definitive resection for patients with renal tumors. This results in fewer tumor spills during surgery and lower postoperative stage.[222] When the histological features of Wilms tumors from patients who underwent immediate surgery were compared with the histological features of patients who received preoperative chemotherapy, preoperative chemotherapy was shown to significantly alter the histology, with fewer blastemal and mixed histology types in the tumors. Additionally, there were fewer stage III tumors in the preoperative chemotherapy group.[223]

Sources: 222 · 223

Both SIOP and COG treat infants younger than 6 months with a primary nephrectomy.[224]

Sources: 224

This summary focuses on the NWTS (now COG RTC) results and studies.

The major treatment and study conclusions of NWTS-1, NWTS-2, NWTS-3, NWTS-4, and NWTS-5 are as follows:

Sources: NWTS-5

Routine, postoperative radiation therapy of the flank is not necessary for children with stage I tumors or stage II tumors with FH when postnephrectomy combination chemotherapy consisting of vincristine and dactinomycin is administered.[221]

Sources: 221

The prognosis for patients with stage III FH is best when treatment includes either (a) dactinomycin, vincristine, doxorubicin, and 10.8 Gy of radiation therapy to the flank; or (b) dactinomycin, vincristine, and 20 Gy of radiation therapy to the flank. Whole-abdominal radiation is indicated for extensive intraperitoneal disease or widespread intraperitoneal tumor spill with possible boost to gross residual disease.[221]

Sources: 221

The addition of cyclophosphamide at the protocol dose (10 mg/kg/d for 3 days every 6 weeks) to the combination of vincristine, dactinomycin, and doxorubicin does not improve prognosis for patients with stage IV FH tumors.[221]

Sources: 221

A single dose of dactinomycin per course (stages I–II FH, stage I anaplastic histology, stage III FH, stages III–IV, or stages I–IV clear cell sarcoma of the kidney) is equivalent to the divided-dose courses, results in the same EFS, achieves greater dose intensity, and is associated with less toxicity and expense.[225]

Sources: 225

Eighteen weeks of therapy is adequate for patients with stage I and stage II FH, and stage III and IV patients can be treated with 6 months of therapy instead of 15 months.[180,219,225-227]

Sources: 180 · 219 · 225 · 227

Gain of 1q is associated with inferior survival in patients with unilateral FH Wilms tumor. It is the single most powerful predictor of outcome, and in the presence of 1q gain, neither 1p nor 16q loss is significant. In the absence of 1q gain in unilateral FH Wilms tumor, 1p and/or 16q loss retain some prognostic significance and are associated with a higher risk of recurrence.[107,110]

Sources: 107 · 110

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment option overview for Wilms tumor

Surgery

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

The following operative principles have also evolved from NWTS (COG) trials:

The most important role for the surgeon is to ensure complete tumor removal without rupture and assess the extent of disease. Radical nephrectomy and lymph node sampling via a transabdominal or thoracoabdominal incision is the procedure of choice.[228] A flank incision is not performed because it provides limited exposure to the kidney. For patients with resectable tumors, preoperative biopsy or intraoperative biopsy is not performed because either would upstage the tumor in the current COG staging system.[228]

Sources: 228 · 228

Routine exploration of the contralateral kidney is not necessary if technically adequate imaging studies do not suggest a bilateral process. If the initial imaging studies suggest bilateral kidney involvement, treatment approaches should facilitate renal-sparing surgery.[164]

Sources: 164

About 2% of Wilms tumor cases have ureteral involvement. The presence of gross hematuria, nonfunctioning kidney, or hydronephrosis suggests the tumor may extend into the ureter, and cystoscopy is recommended. En bloc resection to avoid tumor spill is recommended.[229]

Sources: 229

The surgeon needs to be aware of the risk of intraoperative spill, especially in patients who have right-sided and large tumors, as noted in a review of cases of intraoperative spill among 1,131 patients registered on COG study AREN03B2 (NCT00898365).[230]

Sources: AREN03B2 · 230

Even if stage IV disease (e.g., pulmonary metastases) is evident on imaging, resection of the renal tumor should be considered. Treatment of local stage I or II Wilms tumor in the setting of distant metastasis does not require local radiation therapy.

Renal-sparing surgery remains controversial and is not supported by the data, except for children with the following:[231,232]; [233][Level of evidence C1]

Sources: 231 · 232 · 233 · Level of evidence C1

A solitary kidney.

Predisposition to bilateral tumors. Some children who are predisposed to bilateral tumors and who have very small tumors detected by screening ultrasonography may be considered for renal-sparing surgery to preserve renal tissue.[231]

Sources: 231

Horseshoe kidney. Wilms tumor arising in a horseshoe kidney is rare, and accurate preoperative diagnosis is important for planning the operative approach. Primary resection is possible in most cases. Inoperable cases can usually be resected after chemotherapy.[234]

Sources: 234

Wilms tumor in infants with Denys-Drash or Frasier syndrome (to delay the need for dialysis).

Renal-sparing surgery does not appear to be feasible for most patients at the time of diagnosis because of the location of the tumor within the kidney, even in patients with very low-risk tumors.[235] In North America, renal-sparing surgery (partial nephrectomy) of unilateral Wilms tumor after administration of chemotherapy to shrink the tumor mass is considered investigational.[236,237]

Sources: 235 · 236 · 237

Wilms tumor rarely invades adjacent organs; therefore, resection of contiguous organs is seldom indicated. There is an increased incidence of complications occurring in more extensive resections that involve removal of additional organs beyond the diaphragm and adrenal gland. This finding has led to the recommendation in current COG protocols that patients in whom nephrectomy will require removal of additional organs should be considered for initial biopsy, neoadjuvant chemotherapy, and then secondary resection.[238] Primary resection of liver metastasis is not recommended.[239]

Sources: 238 · 239

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment option overview for Wilms tumor / Surgery

Lymph node sampling

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Lymph node status is a major long-term predictor of outcome in patients with Wilms tumor.[228] Data from Wilms tumor studies suggest that the lymph node number and location may impact therapy and outcome, although NWTS and COG renal tumor protocols have never defined the number of lymph nodes or locations of lymph nodes to be sampled.[228] The ideal number of lymph nodes that should be sampled remains unknown.

Sources: 228 · 228

The 5-year OS rate was lower for patients with 0 lymph nodes sampled (87% vs. 91% for 1–5 lymph nodes, 93% for 6–10 lymph nodes, 95% for >10 lymph nodes; P = .005). Multivariate analysis confirmed a survival advantage for patients having 1 to 5 lymph nodes sampled (HR, 0.6; P = .016), 6 to 10 lymph nodes sampled (HR, 0.521; P = .048), and >10 lymph nodes sampled (HR, 0.403; P = .039), compared with patients with 0 lymph nodes examined.[240]

Sources: 240

In NWTS-5, failure to sample lymph nodes was associated with higher risk of relapse in stage I and II patients.[241] AREN0532 showed similar results with a poorer EFS observed for patients who did not have a lymph node biopsy. The EFS for stage III patients without lymph node sampling was 84% (n = 148), compared with 89% for those patients who had lymph node sampling (n = 387) (P = .067).[242]

Sources: 241 · 242

Hilar and periaortic lymph node sampling is appropriate even if the nodes appear normal.[228,240] Furthermore, any suspicious node basin is sampled. Margins of resection, residual tumor, and any suspicious node basins are marked with titanium clips.

Sources: 228 · 240

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment option overview for Wilms tumor / Surgery

Pleural effusions

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

The presence of a pleural effusion does not appear to necessitate a change in therapy. In a multi-institutional retrospective review of 1,259 children with newly diagnosed Wilms tumor, 94 (7.5%) had a pleural effusion.[169][Level of evidence C1]

Sources: 169 · Level of evidence C1

Patients with a pleural effusion were older than those without a pleural effusion (median, 4.3 vs. 3.5 years; P = .004) and were more likely to present with advanced-stage disease (local stage III, 83% vs. 51.6%; P = .0001).

Only 14 patients underwent a thoracentesis, 3 of whom had pulmonary parenchymal metastatic disease at the time of diagnosis.

Thirty patients with a pleural effusion received chest radiation therapy as part of their therapy, 29 of whom had pulmonary or mediastinal metastases.

Sixty-four patients with a pleural effusion did not receive chest radiation therapy, 59 of whom did not have associated pulmonary disease at the time of diagnosis.

Only three patients with a pleural effusion and no history of pulmonary disease later experienced a relapse with thoracic disease.

For the entire cohort of patients with pleural effusions, the EFS rate was 86.2%, and the OS rate was 91.5%.

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment option overview for Wilms tumor

Chemotherapy

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Preoperative chemotherapy before nephrectomy is indicated in the following situations, which have been listed previously under situations requiring a biopsy:[228,238,243-246]

Sources: 228 · 238 · 243 · 246

Wilms tumor in a solitary kidney.

Synchronous bilateral Wilms tumor.

Extension of tumor thrombus in the inferior vena cava above the level of the hepatic veins. About 4% of Wilms tumor patients present with inferior vena cava or atrial involvement, and 11% of patients present with renal vein involvement. Embolization of a caval thrombus to the pulmonary artery is rare but can be lethal, and the presence of a thrombus must be identified preoperatively to prevent this occurrence and guide treatment.[165,178]

Sources: 165 · 178

Tumor involves contiguous structures whereby the only means of removing the kidney tumor requires removal of the other structures (e.g., spleen, pancreas, or colon but excluding the adrenal gland).

Inoperable Wilms tumor.

Pulmonary compromise resulting from extensive pulmonary metastases.

For more information, see the Diagnostic and Staging Evaluation for Wilms Tumor section.

Sources: Diagnostic and Staging Evaluation for Wilms Tumor

A large contemporary series included 124 patients with Wilms tumor and intracaval extension who were treated at North American centers. Most patients (82%) received a three-drug neoadjuvant chemotherapy regimen. Neoadjuvant chemotherapy reduced the need for cardiopulmonary bypass and also avoided the complexity of intrahepatic caval thrombus resection.[246]

Sources: 246

The thrombus level regression rate was 45% overall, with suprahepatic level showing the best response (62%).

Cardiopulmonary bypass was potentially avoided in 67% of patients.

The perioperative complication rate was significantly lower after neoadjuvant chemotherapy (25%), compared with up-front surgery (55%; P = .005).

Overall, the 2-year EFS rate was 93%, and the OS rate was 96%. The rates were higher for patients with FH tumors (98% for FH vs. 82% for unfavorable/anaplastic histology tumors).

Incomplete resection and viable thrombus cells did not affect EFS or OS.

Preoperative chemotherapy follows a biopsy. The biopsy may be performed through a flank approach.[178,247-251] Adequate tissue is essential for accurate histological assessment and molecular studies. Preoperative chemotherapy includes doxorubicin in addition to vincristine and dactinomycin unless anaplastic histology is present. In these cases, chemotherapy then includes treatment with regimen I (see Table 2). The chemotherapy generally makes tumor removal easier by decreasing the size and vascular supply of the tumor. Chemotherapy may also reduce the frequency of surgical complications.[173,178,238,243,252,253]

Sources: 178 · 247 · 251 · Table 2 · 173 · 178 · 238 · 243 · 252 · 253

In a meta-analysis that investigated the effect of neoadjuvant chemotherapy on thrombus viability for Wilms tumor where intravascular extension was defined as any Wilms tumor with extension beyond the renal vein. Neoadjuvant chemotherapy was found to be effective in achieving thrombus nonviability in around 50% of patients with tumor extension into the inferior vena cava. No added benefit was identified from extended cycles of neoadjuvant chemotherapy. Most patients received chemotherapy consisting of dactinomycin and vincristine with or without doxorubicin.[254]

Sources: 254

In North America, the use of preoperative chemotherapy in patients with evidence of a contained preoperative rupture has been suggested to avoid intraoperative spill, but this is controversial.[255,256] The preoperative diagnosis of a contained retroperitoneal rupture on CT is difficult, even for experienced pediatric radiologists.[162]

Sources: 255 · 256 · 162

All infants younger than 12 months (including newborns) who will be treated with chemotherapy require a 50% reduction in chemotherapy dose compared with the dose given to older children.[257] Dosing for infants (younger than 12 months) is calculated per kilogram of weight, not body surface area. This reduction diminishes the toxic effects reported in children in this age group enrolled in NWTS studies while maintaining an excellent overall outcome.[258]

Sources: 257 · 258

Liver function tests in children with Wilms tumor are monitored closely during the early course of therapy because severe hepatic toxic effects (including sinusoidal obstructive syndrome, which was previously called veno-occlusive disease) have been reported in these patients.[259,260] In a cohort of 8,862 children with renal tumors from the NWTS-3, -4, and -5 trials, the incidence of severe hepatopathy was low (0.8%). Careful reintroduction of chemotherapy appeared to be feasible for most patients who developed severe chemotherapy- and/or radiation therapy–induced liver toxicity.[261] Dactinomycin or doxorubicin should not be administered during radiation therapy.

Sources: 259 · 260 · 261

Patients who develop renal failure while undergoing therapy can continue chemotherapy with vincristine, dactinomycin, and doxorubicin. Vincristine and doxorubicin can be given at full doses. However, dactinomycin is associated with severe neutropenia. Dose reductions for these agents may not be necessary, but accurate pharmacological and pharmacokinetic studies are needed while the patient is receiving therapy.[262,263]

Sources: 262 · 263

Augmentation of therapy improves EFS for patients with FH Wilms tumor and loss of heterozygosity of 1p and 16q. In the AREN0532 (NCT00352534) and AREN0533 (NCT00379340) trials, patients with stage I and stage II FH Wilms tumor who were treated with the DD-4A regimen (dactinomycin, vincristine, and doxorubicin) demonstrated a 4-year EFS rate of 87.3%, compared with the 4-year EFS rate of 68.8% (P = .042) for stage I and stage II patients treated on the NWTS-5 trial. Patients with stage III and stage IV disease had a 4-year EFS rate of 90.2% when treated with regimen M (see Table 2), compared with a 61.3% 4-year EFS rate (P = .001) for stage III and stage IV patients treated on the NWTS-5 trial. Trends toward improved 4-year OS rates were seen in stage I and II patients and in stage III and IV patients.[264][Level of evidence C2]

Sources: AREN0532 (NCT00352534) · AREN0533 (NCT00379340) · NWTS-5 · Table 2 · 264 · Level of evidence C2

Postoperative radiation therapy to the tumor bed is required when a biopsy is performed or in the setting of local tumor stage III. In a study of 1,488 patients with Wilms tumors who underwent surgery and radiation therapy, delay in starting radiation therapy after surgery of greater than 14 days was associated with an increased risk of mortality for patients with nonmetastatic Wilms tumor.[265][Level of evidence C1]

Sources: 265 · Level of evidence C1

Table 2 describes the accepted chemotherapy regimens used to treat Wilms tumor.

Sources: Table 2

Table 2. Accepted Chemotherapy Regimens for Wilms Tumor
Regimen NameRegimen Description
Regimen EE-4A [110]Vincristine, dactinomycin × 18 weeks postnephrectomy
Regimen DD-4A [110]Vincristine, dactinomycin, doxorubicin × 24 weeks; baseline nephrectomy or biopsy with subsequent nephrectomy
Regimen I [183]Vincristine, doxorubicin, cyclophosphamide, etoposide × 24 weeks postnephrectomy
Regimen M [266]Vincristine, dactinomycin, doxorubicin, cyclophosphamide, and etoposide with subsequent radiation therapy
Regimen UH1 [267]Vincristine, doxorubicin, cyclophosphamide, carboplatin, and etoposide × 30 weeks + radiation therapy
Regimen UH2 [267]Vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, vincristine, and irinotecan × 36 weeks + radiation therapy

Sources: 110 · 110 · 183 · 266 · 267 · 267

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment option overview for Wilms tumor

Radiation therapy

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Radiation therapy is used to improve local control and treat sites of metastatic disease. Radiation therapy has historically been dependent on stage and histology, but more recently is also guided by the tumor molecular signature.[185]

Sources: 185

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment option overview for Wilms tumor / Radiation therapy

COG approach

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Up-front surgery provides histological confirmation and tumor extent, providing the rationale for adjuvant therapy, including radiation therapy. Besides histology, postoperative risk factors for worse local control include: (1) incomplete resection, (2) positive margins, and (3) nodal involvement. Radiation therapy is not used in patients with stage I or stage II FH Wilms tumor. For patients with FH stage III Wilms tumor, flank or abdominal radiation therapy is used for treatment. In cases of unfavorable histology (focal or diffuse anaplasia), flank or abdominal radiation therapy is indicated for all patients. For more information, see Table 3.

Sources: Table 3

Results of NWTS (COG RTC) trials have shown the following:

Flank radiation therapy covers the tumor bed, involved nodal region, and entire adjacent vertebral bodies at 10.8 Gy in 1.8-Gy fractions. The dose of radiation therapy is based on the results of the NWTS-3 study in which there was no increase in abdominal relapse for stage III FH patients receiving 10 Gy versus 20 Gy with DD-4A chemotherapy.[268]

Sources: 268

Whole-abdominal radiation therapy is 10.5 Gy in 1.5-Gy fractions and is used to treat diffuse spill or peritoneal metastasis.[264]

Sources: 264

In the closed COG AREN0321 (NCT00335556) study, the radiation therapy dose to the tumor bed was 10.8 Gy in 1.8-Gy fractions, with the exception of patients with stage III diffuse anaplasia, where a dose of 19.8 Gy in 1.8-Gy fractions was used. This remains the current standard of treatment.[267]

Sources: AREN0321 (NCT00335556) · 267

Results of the early NWTS studies (1 and 2) suggested that a radiation therapy delay of more than 10 days after surgery resulted in worse local control, particularly in unfavorable histology Wilms tumor.[269,270] However, no difference in local control was found if radiation therapy was delayed more than 10 days after surgery for patients with stages II to IV FH tumors treated on the NWTS-3 or NWTS-4 trials.[103] More recent data from the National Cancer Database confirmed improved survival in patients with nonmetastatic Wilms tumor who received adjuvant radiation therapy less than or equal to 14 days postoperatively.[265]

Sources: 269 · 270 · 103 · 265

Results from the NWTS-3 and NWTS-4 trials indicated that there was no survival benefit of whole-lung irradiation in the setting of lung metastases seen on CT scan only.[271] Current COG guidelines allow for omission of whole-lung irradiation in cases of FH disease without extrapulmonary metastases, loss of heterozygosity at 1p and 16q, and complete response at 6 weeks after vincristine, dactinomycin, and doxorubicin.[185] When whole-lung irradiation is given, a dose of 12 Gy in 1.5-Gy fractions is indicated for children older than 12 months and 10.5 Gy in 1.5-Gy fractions for patients younger than 12 months with pulmonary metastasis.

Sources: 271 · 185

Other sites of metastatic disease in Wilms tumor are uncommon and may include liver, extra-abdominal nodes, brain, and bone. In the COG AREN0533 (NCT00379340) study, the radiation therapy doses being used for patients younger than 16 years are 19.8 Gy in 1.8-Gy fractions to liver and gross residual nodes, 21.6 Gy in 1.8-Gy fractions to the whole brain with a boost of 10.8 Gy in 1.8-Gy fractions to gross metastatic disease in the brain, and 25.2 Gy in 14 fractions for bone metastasis. For patients older than 16 years, the radiation therapy dose to the whole brain and bone is increased to 30.6 Gy in 1.8-Gy fractions.

Sources: AREN0533 (NCT00379340)

Table 3. Radiation Therapy Regimens used in Children’s Oncology Group AREN0532, AREN0533, and AREN0321 Protocols
Local/Locoregional Disease
XRT = radiation therapy.
aRequires whole-abdominal XRT in 1.5 Gy daily fractions. Patients with diffuse unresectable peritoneal implants receive 21 Gy.
bWhole-lung irradiation is given in 1.5 Gy daily fractions.
cNot all patients receive radiation therapy.
dA boost is given for macroscopic disease.
Stage IStage IIStage IIIStage III (diffuse spill, peritoneal metastasis, preoperative rupture)a
Favorable histologyNo XRTNo XRT10.8 Gy10.5 Gy
Focal anaplasia10.8 Gy10.8 Gy10.8 Gy10.5 Gy
Diffuse anaplasia10.8 Gy10.8 Gy19.8 Gy10.5 Gy + 9 Gy boost
Metastatic Disease
Stage IV LungStage IV LiverStage IV BrainStage IV Bone
Favorable histology10.5 Gy for age <12 monthsb,c; 12 Gy for age >12 monthsb,c19.8 Gy +/- 5.4 to 10.8 Gy boostd21.6 Gy + 10.8 Gy boost for age <16 years; 30.6 Gy for age >16 years25.2 Gy for age <16 years; 30.6 Gy for age >16 years
Focal or diffuse anaplasia10.5 Gy for age <12 monthsb; 12 Gy for age >12 monthsb19.8 Gy +/- 5.4 to 10.8 Gy boostd21.6 Gy + 10.8 Gy boost for age <16 years; 30.6 Gy for age >16 years25.2 Gy for age <16 years; 30.6 Gy for age >16 years

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment option overview for Wilms tumor / Radiation therapy

SIOP approach

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Based on the experience of previous SIOP trials, children who need radiation therapy undergo postoperative treatment to the flank and/or metastatic sites. The SIOP 1 to 9 trials demonstrated that preoperative radiation therapy or preoperative chemotherapy decreased the proportion of patients who developed tumor spillage, from more than 20% to 5%. The noninferiority of preoperative chemotherapy to preoperative radiation therapy in the SIOP 5 trial, and the concern over secondary malignancies with preoperative radiation therapy, led SIOP to recommend preoperative chemotherapy as the standard initial treatment.[222] Over time, the percentage of children who were treated with postoperative radiation therapy decreased, from more than 90% to 15% and 25% in SIOP trials 6 to 9, SIOP 93-01, and SIOP-2001, respectively.[220]

Sources: 222 · 220

Abdominal radiation therapy has been omitted for patients with metastatic, local stage III Wilms tumor who had complete necrosis after 6 weeks of preoperative chemotherapy. It was also omitted in patients with stage III Wilms tumor who received 4 weeks of preoperative chemotherapy (n = 19) and had complete necrosis. The outcomes were excellent for both groups of patients with stage III Wilms tumor who had complete necrosis. The 5-year EFS and OS rates were 100% for patients with stage III disease and 95% for patients with metastatic local stage III disease.[272,273]

Sources: 272 · 273

Health professional · Wilms Tumor / Treatment of Wilms Tumor

Treatment of stage I Wilms tumor

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Table 4 provides an overview of the standard treatment options and survival data for patients with stage I Wilms tumor, based on published results.

Sources: Table 4 · stage I Wilms tumor

Table 4. Overview of Standard Treatment Options for Stage I Wilms Tumora
Histology4-Year RFS or EFS4-Year OSTreatmentb
DA = diffuse anaplastic; EFS = event-free survival; FA = focal anaplastic; FH = favorable histology; LOH = loss of heterozygosity; OS = overall survival; RFS = relapse-free survival; XRT = radiation therapy.
aSource: Grundy et al.,[110] Shamberger et al.,[184] Fernandez et al.,[185] Dix et al.,[264] and Daw et al.[274]
bFor chemotherapy regimen descriptions, see Table 2.
cOne patient with a pulmonary relapse 4.12 years after diagnosis.
FH <24 mo/tumor weight <550g90%100%Surgery, including lymph node biopsy only
FH >24 mo/tumor weight >550g94% RFS98%Nephrectomy + lymph node sampling followed by regimen EE-4A
FH with LOH 1p/16q (n = 8)100% EFS100%Nephrectomy + lymph node sampling followed by regimen DD-4A
FA100%100% (n = 8)Nephrectomy + lymph node sampling followed by regimen DD-4A and XRT
DA100%c100% (n = 10)Nephrectomy + lymph node sampling followed by regimen DD-4A and XRT

Sources: 110 · 184 · 185 · 264 · 274 · Table 2

Evidence (surgery only for children younger than 2 years at diagnosis with stage I FH tumor that weighed <550 g):

In the AREN0532 (NCT00352534) trial, the COG validated the findings from the NWTS-5 trial that nephrectomy only is appropriate therapy for patients younger than 2 years at diagnosis with stage I FH Wilms tumor that weighed less than 550 g.

Sources: AREN0532 (NCT00352534) · NWTS-5

The AREN0532 (NCT00352534) trial was designed to confirm the findings from NWTS-5 that adjuvant chemotherapy could be omitted for children younger than 2 years at diagnosis with stage I FH Wilms tumor that weighed less than 550 g. A total of 116 patients met the criteria for very low-risk Wilms tumor and were enrolled on the study.[184,185,275]

Sources: AREN0532 (NCT00352534) · 184 · 185 · 275

The AREN0532 (NCT00352534) trial was designed to confirm the findings from NWTS-5 that adjuvant chemotherapy could be omitted for children younger than 2 years at diagnosis with stage I FH Wilms tumor that weighed less than 550 g. A total of 116 patients met the criteria for very low-risk Wilms tumor and were enrolled on the study.[184,185,275]

Twelve patients relapsed.

The estimated 4-year EFS rate was 89.7%, and the OS rate was 100%.

11p15 methylation status was associated with relapse (20% relapse with loss of heterozygosity, 25% relapse with loss of imprinting, and 3.3% relapse with retention of the normal imprinting [P = .011]).

The risk of developing metachronous Wilms tumor is very low in patients with very low-risk Wilms tumor who lack evidence of an underlying syndrome.

Evidence (treatment of stage I epithelial-predominant FH Wilms tumor):

The COG reported the outcomes for patients of all ages with stage I FH Wilms tumors showing epithelial-predominant histology. Approximately 20% of stage I FH Wilms tumors registered on AREN03B2 were epithelial predominant. In this group of 177 patients with stage I epithelial-predominant FH Wilms tumors, 117 patients were treated with EE-4A, and 57 patients were classified as having a very low-risk Wilms tumor and were treated with observation only.[201][Level of evidence C1]

Sources: 201 · Level of evidence C1

The COG reported the outcomes for patients of all ages with stage I FH Wilms tumors showing epithelial-predominant histology. Approximately 20% of stage I FH Wilms tumors registered on AREN03B2 were epithelial predominant. In this group of 177 patients with stage I epithelial-predominant FH Wilms tumors, 117 patients were treated with EE-4A, and 57 patients were classified as having a very low-risk Wilms tumor and were treated with observation only.[201][Level of evidence C1]

The 4-year EFS rate was 96.2%, and the OS rate was 100%.

There was no statistical difference in EFS and OS based on age at diagnosis (<48 months and >48 months) or treatment (EE-4A vs. observation only).

There were six events: three patients developed contralateral tumors after their initial diagnosis, and two of these patients had received adjuvant chemotherapy for their initial tumors. Three patients developed metastatic disease, and all of these patients had previously received EE-4A as their primary therapy.

Evidence (treatment of anaplastic stage I Wilms tumor):

The AREN0321 (NCT00335556) study demonstrated that outcomes for patients with stage I anaplastic Wilms tumor were improved with the addition of doxorubicin and flank radiation therapy to vincristine/dactinomycin therapy.[274]

Sources: AREN0321 (NCT00335556) · 274

The AREN0321 (NCT00335556) study demonstrated that outcomes for patients with stage I anaplastic Wilms tumor were improved with the addition of doxorubicin and flank radiation therapy to vincristine/dactinomycin therapy.[274]

The 4-year EFS and OS rate estimates were 100% in AREN0321, compared with 70% and 81.5%, respectively, in an updated analysis of 27 patients from NWTS-5 (median follow-up, 13.3 years). One patient with diffuse anaplasia relapsed 4.12 years after diagnosis on the AREN0321 trial.

Sources: NWTS-5

The addition of doxorubicin and radiation therapy to AREN0321 was based on the pattern of relapse observed in stage I anaplastic Wilms tumor in the abdomen and distant sites in the NWTS-5 trial.

Retrospective analysis of all patients with stage I anaplastic Wilms tumor treated on NWTS-1 through NWTS-5 and AREN0321 showed a significant improvement in EFS for patients treated with doxorubicin (4-year EFS rate, 97.2% vs. 77.5%; P = .01), but no difference in EFS according to flank radiation therapy was shown (4-year EFS rate, 91.7% vs. 80.2%; P = .15).

The rate of local recurrence was low (3.6%) and appeared to be similar for patients who received flank radiation therapy (4%) and patients who did not receive flank radiation therapy (6.2%). Local relapse occurred only in patients with diffuse anaplasia.

Health professional · Wilms Tumor / Treatment of Wilms Tumor

Treatment of stage II Wilms tumor

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Table 5 provides an overview of the standard treatment options and survival data for patients with stage II Wilms tumor, based on published results.

Sources: Table 5 · stage II Wilms tumor

Table 5. Overview of Standard Treatment Options for Stage II Wilms Tumora
Histology4-Year RFS or EFS4-Year OSTreatmentb
DA = diffuse anaplastic; EFS = event-free survival; FA = focal anaplastic; FH = favorable histology; LOH = loss of heterozygosity; OS = overall survival; RFS = relapse-free survival; XRT = radiation therapy.
aSource: Grundy et al.,[110] Dome et al.,[183] Dix et al.,[264] Daw et al.,[267] and Armstrong et al.[276]
bFor chemotherapy regimen descriptions, see Table 2.
FH86% RFS98%Nephrectomy + lymph node sampling followed by regimen EE-4A
FH LOH 1p/16q (n = 24)83% EFS100%Nephrectomy + lymph node sampling followed by regimen DD-4A
FA100% EFS100% (n = 2)Nephrectomy + lymph node sampling followed by abdominal XRT and regimen DD-4A
DA84% EFS84% (n = 19)Nephrectomy + lymph node sampling followed by abdominal XRT and regimen UH1

Sources: 110 · 183 · 264 · 267 · 276 · Table 2

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment of stage II Wilms tumor

Treatment of stage II patients with intraoperative spill

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

In a review of 499 patients from the NWTS-4 trial with stage II FH Wilms tumor, 95 of the patients experienced tumor spill. The 8-year RFS and OS rates for patients who experienced intraoperative tumor spill and were treated with vincristine and dactinomycin without flank radiation therapy were lower (75.7% and 90.3%, respectively) than the rates for those who did not experience tumor spill (85% and 95.6%, respectively). None of these differences achieved statistical significance.[217]

Sources: 217

On the NWTS-3, NWTS-4, and NWTS-5 trials, patients with intraoperative spill were divided into two groups: (1) those with diffuse spillage involving the whole abdominal cavity; and (2) those with local spillage confined to the flank. Patients with diffuse spillage were treated with radiation therapy to the entire abdomen and three-drug chemotherapy (vincristine, dactinomycin, and doxorubicin), whereas patients with local spillage were treated with vincristine and dactinomycin only. Based on an analysis of patients treated on NWTS-3 and NWTS-4 indicating that patients with stage II disease and local spillage had inferior OS compared with patients with stage II disease without local spillage, COG studies treat patients with local spillage with doxorubicin and flank radiation.[277] This approach is controversial and has not been tested; therefore, it should not be considered standard.

Sources: NWTS-5 · 277

Health professional · Wilms Tumor / Treatment of Wilms Tumor

Treatment of stage III Wilms tumor

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Table 6 provides an overview of the standard treatment options and survival data for patients with stage III Wilms tumor, based on published results.

Sources: Table 6 · stage III Wilms tumor

For information about patients classified as stage III purely based on local spill, see the Treatment of stage II Wilms tumor section.

Sources: Treatment of stage II Wilms tumor

Table 6. Overview of Standard Treatment Options for Stage III Wilms Tumora
Histology4-Year RFS or EFS4-Year OSTreatmentb
DA = diffuse anaplastic; EFS = event-free survival; FA = focal anaplastic; FH = favorable histology; LOH = loss of heterozygosity; OS = overall survival; RFS = relapse-free survival; XRT = radiation therapy.
aSource: Grundy et al.,[110] Dome et al.,[183] Fernandez et al.,[242] Dix et al.,[264] Daw et al.,[267] and Armstrong et al.[276]
bFor chemotherapy regimen descriptions, see Table 2.
FH (all patients)88% EFS97%Nephrectomy + lymph node sampling followed by abdominal XRT and regimen DD-4A
FH (without LOH of 1p and/or 16q) and positive lymph nodes (n = 109)82% EFS97%Nephrectomy + lymph node sampling followed by abdominal XRT and regimen DD-4A
FH (without LOH of 1p and/or 16q) and negative lymph nodes (n = 169)97% EFS99%Nephrectomy + lymph node sampling followed by abdominal XRT and regimen DD-4A
FH (with LOH of 1p and 16q) (n = 31)87% EFS94%Nephrectomy + lymph node sampling followed by abdominal XRT and regimen M
FH (with LOH of 1p and 16q) and negative lymph nodes (n = 12)92%92%Nephrectomy + lymph node sampling followed by abdominal XRT and regimen M
FH (with LOH of 1p or 16q) and negative lymph nodes (n = 13)85%92%Nephrectomy + lymph node sampling followed by abdominal XRT and regimen M
FH (with LOH of 1p or 16q) and negative lymph nodes (n = 68)87%97%Nephrectomy + lymph node sampling followed by abdominal XRT and regimen DD-4A
FH (with LOH of 1p or 16q) and positive lymph nodes (n = 48)74%92%Nephrectomy + lymph node sampling followed by abdominal XRT and regimen DD-4A
FA70% RFS79% (n = 10)Nephrectomy + lymph node sampling followed by abdominal XRT and regimen DD-4A
FA (preoperative treatment)71% RFS71% (n = 7)Preoperative treatment with regimen DD-4A followed by nephrectomy + lymph node sampling and abdominal XRT
DA46% EFS53% (n = 16)Preoperative treatment with regimen I followed by nephrectomy + lymph node sampling and abdominal XRT
DA82% EFS91% (n = 23)Immediate nephrectomy + lymph node sampling followed by abdominal XRT and regimen UH1

Sources: 110 · 183 · 242 · 264 · 267 · 276 · Table 2

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment of stage III Wilms tumor

Radiation therapy

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Early initiation of radiation therapy is a critical component of multimodal therapy for patients with nonmetastatic Wilms tumor. In a review of 1,488 patients with Wilms tumor who underwent surgery and radiation therapy, a surgery-to-radiation therapy interval of greater than 14 days was associated with an increased risk of mortality (HR, 2.13; P = .013). This underscores the importance of initiating radiation therapy within 14 days of surgery, which is specified in Wilms tumor treatment protocols.[265][Level of evidence C1]

Sources: 265 · Level of evidence C1

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment of stage III Wilms tumor

Loss of heterozygosity of 1p or 16q

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Loss of heterozygosity of 1p or 16q was shown to influence EFS but not OS in 635 patients with stage III FH Wilms tumor enrolled in the COG AREN0532 or AREN03B2 protocols. When combined, a negative lymph node status (related to histology) and a negative loss of heterozygosity status (related to the primary tumor) was a strong predictor of excellent EFS and OS.[278]

Sources: 278

Patients who had lymph nodes sampled during surgery had improved EFS (4-year EFS rate, 90.3%) relative to patients without lymph nodes sampled (4-year EFS rate, 80.0%; P = .0037). No difference was seen in OS whether lymph nodes were sampled (4-year OS rates, 97.0% for patients with lymph nodes sampled vs. 94.9% for those without lymph nodes sampled; P = .078).

Patients with positive lymph nodes at nephrectomy had worse EFS than those with negative lymph nodes (83.5% vs. 94.2% at 4-years; HR, 2.78; P = .00017). A borderline significant effect was observed for OS (4-year OS rates, 95.1% vs. 98.2%; HR, 2.50; P = .054).

An analysis of patients with stage III Wilms tumor according to lymph node status (positive or negative) and singular loss of heterozygosity of 1p or 16q status (positive for one or negative for both) is shown in Table 7.

Sources: Table 7

An analysis of patients with stage III Wilms tumor according to lymph node status (positive or negative) and singular loss of heterozygosity of 1p or 16q status (positive for one or negative for both) is shown in Table 7.

Table 7. An analysis of Patients with Stage III Wilms Tumor According to Lymph Node Status and Singular LOH 1p or 16q Status
Lymph Node StatusLOH 1p or 16q4-Year EFS RateaHRb
- = negative; + = positive; EFS = event-free survival; HR = hazard ratio; LOH = loss of heterozygosity.
aCompared with patients both negative for lymph node and singular LOH, a significant difference in EFS across the groups was observed (log-rank P < .0001).
bOverall survival did not reach statistical significance between groups.
--96.2%- (n = 212)
-+1p or 16q89.5%3.04 (n = 72)
++1p73.9%6.33 (n = 37)
++16q79.3%
+-86.0%3.57 (n = 104)

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment of stage III Wilms tumor

Loss of heterozygosity of 1p and 16q

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Therapy was augmented for patients with loss of heterozygosity of 1p and 16q who were enrolled in the AREN0533 (NCT00379340) trial. Patients with stage III and stage IV Wilms tumor with loss of heterozygosity were treated with regimen M. The 4-year EFS rate was 90.2%, and the OS rate was 96.1%, compared with a 4-year EFS rate of 61.3% (P = .001) and a 4-year OS rate of 86.0% (P = .087) for patients in the NWTS-5 trial. The study suggested an improvement in survival, but it was not powered to detect differences in survival.[264][Level of evidence C2]

Sources: AREN0533 (NCT00379340) · 264 · Level of evidence C2

Health professional · Wilms Tumor / Treatment of Wilms Tumor

Treatment of stage IV Wilms tumor

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Table 8 provides an overview of the standard treatment options and survival data for patients with stage IV Wilms tumor, based on published results.

Sources: Table 8 · stage IV Wilms tumor

Table 8. Overview of Standard Treatment Options for Stage IV Wilms Tumora
Histology4-Year RFS or EFS4-Year OSTreatmentb
CR = complete response; DA = diffuse anaplasia; EFS = event-free survival; FA = focal anaplasia; FH = favorable histology; LOH = loss of heterozygosity; OS = overall survival; RFS = relapse-free survival; XRT = radiation therapy.
aSource: Grundy et al.,[110] Dome et al.,[183] Dix et al.,[266] Dix et al.,[264] Daw et al.,[267] Benedetti et al.,[279] and Armstrong et al.[276]
bFor chemotherapy regimen descriptions, see Table 2.
cAbdominal XRT is planned according to local stage of renal tumor.
dPulmonary XRT is reserved for patients with chest x-ray/chest computed tomography evidence of pulmonary metastases.
eFor more information, see the AREN0533 (NCT00379340) and AREN0321 (NCT00335556) studies.
FH (with isolated lung nodules)85% EFS96%Nephrectomy + lymph node sampling, followed by abdominal XRT,c +/- bilateral pulmonary XRT,d and regimen DD-4A or regimen Me
FH (no LOH of 1p and 16q) with isolated lung nodules with CR to DD-4A80% EFS96%Nephrectomy + lymph node sampling, followed by abdominal XRTc and regimen DD-4A
FH (no LOH of 1p and 16q) with isolated lung nodules with incomplete response to DD-4A99% EFS95%Nephrectomy + lymph node sampling, followed by abdominal XRTc and bilateral pulmonary XRTd and regimen M
FH (LOH of 1p and 16q) with isolated lung nodules (n = 18)100%100%Nephrectomy + lymph node sampling followed by abdominal XRTc and bilateral pulmonary XRTd and regimen M
FH (with LOH of 1p and/or 16q) (n = 20)95% EFS100%Nephrectomy + lymph node sampling, abdominal XRTc radiation to sites of metastases, and regimen M
FH with extrapulmonary metastases, with or without lung metastases76% EFS89%Nephrectomy + lymph node sampling followed by abdominal XRTc, regimen M, and local control of other metastatic sites; if lung metastases are present, bilateral pulmonary XRTd
FA80% EFS80% (n = 5)Nephrectomy + lymph node sampling, followed by abdominal XRT,c radiation to sites of metastases, bilateral pulmonary XRT,d and regimen UH1/revised UH1 (AREN0321, consisting of vincristine, doxorubicin, cyclophosphamide, carboplatin, and etoposide)
DA33% EFS33% (n = 10)Immediate nephrectomy + lymph node sampling followed by abdominal XRT,c radiation to sites of metastases, whole-lung XRT,d and regimen I
DA (preoperative treatment)60% EFS70% (n = 10)Preoperative treatment with regimen UH2 followed by nephrectomy + lymph node sampling, followed by abdominal XRT,c radiation to sites of metastases, and whole-lung XRTd

Sources: 110 · 183 · 266 · 264 · 267 · 279 · 276 · Table 2 · AREN0533 (NCT00379340) · AREN0321 (NCT00335556)

Stage IV disease is defined by the presence of hematogenous metastases to the lung, liver, bone, brain, or other sites, with the lung being the most common site. The presence of liver metastases at diagnosis is not an independent adverse prognostic factor in patients with stage IV Wilms tumor.[239]

Sources: 239

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment of stage IV Wilms tumor

Chromosome 1q gain

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

In the AREN0533 (NCT00379340) trial, 30% of patients with stage IV pulmonary disease had 1q gain. These patients trended toward worse EFS, regardless of lung response and whether they received regimen DD-4A or M.[266] Patients in this trial with stage IV lung-only disease who had a rapid complete response to DD-4A and did not receive pulmonary radiation had a lower EFS compared with patients without 1q gain (4-year EFS rates, 57% vs. 86%; P = .0013). The 4-year OS rate, although not statistically significant, was better in patients without 1q gain compared with patients with 1q gain and pulmonary disease (97% vs. 89%; P = .16).[266] Patients who were slow incomplete responders with pulmonary-only disease and 1q gain (treated with DD-4A followed by pulmonary radiation therapy and regimen M) had 4-year EFS and OS rates of 86% and 93%, respectively. In comparison, patients with slow incomplete response without 1q gain had 4-year EFS and OS rates of 92% and 96%, respectively.[266]

Sources: AREN0533 (NCT00379340) · 266 · 266 · 266

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment of stage IV Wilms tumor

Treatment of pulmonary nodules and metastases

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Historically, chest x-rays were used to detect pulmonary metastases. The introduction of CT created controversy because many patients had lung nodules detected by chest CT scans that were not seen on chest x-rays. Management of newly diagnosed patients with FH Wilms tumor who have lung nodules detected only by CT scans (with negative chest x-ray) has elicited controversy as to whether they need to be treated with additional intensive treatment that is accompanied by acute and late toxicities.

Evidence (treatment of pulmonary nodules detected by chest CT scan only):

A retrospective review of 186 patients from NWTS-4 and NWTS-5 with CT-only–detected lung nodules reported on the use of doxorubicin, vincristine, and dactinomycin versus the use of two drugs.[280]

Sources: NWTS-5 · 280

A retrospective review of 186 patients from NWTS-4 and NWTS-5 with CT-only–detected lung nodules reported on the use of doxorubicin, vincristine, and dactinomycin versus the use of two drugs.[280]

Patients who received doxorubicin, vincristine, and dactinomycin with or without lung irradiation had a 5-year EFS rate of 80% versus an EFS rate of 56% for patients receiving only two drugs (P = .004).

There was no difference in EFS according to whether the lung was irradiated.

There was no difference in the 5-year OS rate (87% vs. 86%).

Retrospective studies from Europe have examined the impact of omitting pulmonary radiation in patients with pulmonary metastases diagnosed by chest x-ray. European investigators omitted radiation from the treatment of most patients with Wilms tumor and pulmonary metastases as identified on chest x-ray who were treated on the SIOP-93-01 (NCT00003804) trial. The European approach to renal tumors differs from the approach used in North America. All patients who were shown to have a renal tumor by imaging underwent 9 weeks of prenephrectomy chemotherapy consisting of vincristine, dactinomycin, and doxorubicin.

Sources: SIOP-93-01 (NCT00003804)

Evidence (omission of pulmonary irradiation):

In a retrospective SIOP study, 234 newly diagnosed patients with Wilms tumor presenting with pulmonary metastases were treated according to the response of the pulmonary metastases to the prenephrectomy chemotherapy.[281]

Sources: 281

In a retrospective SIOP study, 234 newly diagnosed patients with Wilms tumor presenting with pulmonary metastases were treated according to the response of the pulmonary metastases to the prenephrectomy chemotherapy.[281]

Patients who were in complete remission (67%) after 6 weeks of therapy continued with the same chemotherapy and did not require radiation to their lungs.

In a retrospective SIOP study, 234 newly diagnosed patients with Wilms tumor presenting with pulmonary metastases were treated according to the response of the pulmonary metastases to the prenephrectomy chemotherapy.[281] › Patients who were in complete remission (67%) after 6 weeks of therapy continued with the same chemotherapy and did not require radiation to their lungs.

The 5-year EFS rate was 77%, and the OS rate was 88%.

In a retrospective SIOP study, 234 newly diagnosed patients with Wilms tumor presenting with pulmonary metastases were treated according to the response of the pulmonary metastases to the prenephrectomy chemotherapy.[281]

Patients who had residual pulmonary metastases were evaluated for metastasectomy.

In a retrospective SIOP study, 234 newly diagnosed patients with Wilms tumor presenting with pulmonary metastases were treated according to the response of the pulmonary metastases to the prenephrectomy chemotherapy.[281] › Patients who had residual pulmonary metastases were evaluated for metastasectomy.

Thirty-seven patients (17%) obtained complete remission with surgery, and their outcome was similar to that of the group of patients who were treated with chemotherapy. Tumor viability in the resected pulmonary metastases was not a factor for omitting radiation therapy.

The 5-year EFS rate was 84%, and the OS rate was 92%.

In a retrospective SIOP study, 234 newly diagnosed patients with Wilms tumor presenting with pulmonary metastases were treated according to the response of the pulmonary metastases to the prenephrectomy chemotherapy.[281]

Patients with residual pulmonary metastases that were incompletely resected or inoperable received more aggressive chemotherapy consisting of ifosfamide/anthracycline alternating with carboplatin/etoposide for 9 weeks.

In a retrospective SIOP study, 234 newly diagnosed patients with Wilms tumor presenting with pulmonary metastases were treated according to the response of the pulmonary metastases to the prenephrectomy chemotherapy.[281] › Patients with residual pulmonary metastases that were incompletely resected or inoperable received more aggressive chemotherapy consisting of ifosfamide/anthracycline alternating with carboplatin/etoposide for 9 weeks.

Patients showing a complete remission at that time were spared pulmonary radiation and continued with chemotherapy, whereas patients with residual pulmonary metastases continued with additional chemotherapy (to complete 34 weeks) and pulmonary irradiation. The 5-year OS rate was 48%, compared with the OS rates for patients who responded to chemotherapy alone (88%) and those who underwent metastasectomy (92%) (P < .001).

Patients with high-risk histologies, such as anaplastic Wilms tumor, were treated with more aggressive chemotherapy but had a poorer outcome, compared with that of patients with nonanaplastic histologies (5-year OS rate, 33% vs. 87%; P < .001).

Based on the European experience, the COG AREN0533 (NCT00379340) study applied a new strategy for patients with FH Wilms tumor and isolated lung metastases to improve EFS while reducing exposure to lung irradiation. Therapy was adjusted based on lung nodule response and tumor-specific loss of heterozygosity at 1p and 16q.[266][Level of evidence C2]

Sources: AREN0533 (NCT00379340) · 266 · Level of evidence C2

Based on the European experience, the COG AREN0533 (NCT00379340) study applied a new strategy for patients with FH Wilms tumor and isolated lung metastases to improve EFS while reducing exposure to lung irradiation. Therapy was adjusted based on lung nodule response and tumor-specific loss of heterozygosity at 1p and 16q.[266][Level of evidence C2]

Of the 292 patients enrolled in the study, 133 patients (42%) showed a complete lung nodule response after 6 weeks of DD-4A (vincristine, dactinomycin, doxorubicin) and continued receiving the same chemotherapy without lung radiation therapy. The 4-year EFS rate was 80%, and OS rate was 96%.

Patients who had an incomplete lung nodule response (n = 145) or loss of heterozygosity at 1p/16q (n = 18) received lung radiation therapy and four cycles of cyclophosphamide/etoposide in addition to the DD-4A drugs (regimen M). The 4-year EFS rate was 89%, and the OS rate was 95% for the incomplete lung nodule response group without loss of heterozygosity. Of the patients with pulmonary metastases only and loss of heterozygosity, the 4-year EFS and OS rates were 100%.

In a post hoc analysis of 1q gain in 212 patients enrolled in AREN0533 who had DNA available, patients with lung nodule complete remission with 1q gain had a significantly worse 4-year EFS rate (57% vs. 86%, P = .001) and trend toward inferior OS rates (89% vs. 97%). Relapses were predominantly pulmonary. There was no difference in outcome for patients with incomplete lung nodule response based on 1q gain.

Regimen M has a higher potential for late effects (increased risk of secondary leukemias and risk of infertility related to a cumulative dose of cyclophosphamide of 8.8 g/m2).

COG showed that initial lung radiation therapy could be avoided in approximately 40% of patients. OS was excellent; however, there was a trend toward more events than expected (expected, 15% and observed, 20%; P = .052).

Although fewer patients were spared pulmonary radiation when treated in the COG trial than in the European trials, it is important to note several differences between the studies and why the studies cannot be directly compared.[266,281] Patients in Europe receive a more dose-dense regimen of dactinomycin and doxorubicin before their pulmonary metastases are reevaluated than do patients in North America (135 ug/kg dactinomycin and 100 mg/m2 doxorubicin in Europe, compared with 45 ug/kg dactinomycin and 45 mg/m2 of doxorubicin in North America). European studies allow lung radiation therapy to be omitted for patients with a complete remission achieved by chemotherapy or pulmonary metastasectomy, whereas radiation therapy was only omitted in the United States for patients with a complete remission using chemotherapy alone. Imaging studies were not centrally reviewed in the European studies, whereas they were in the United States, and the definition of complete remission may have been more stringent in the AREN0533 (NCT00379340) trial.

Sources: 266 · 281 · AREN0533 (NCT00379340)

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment of stage IV Wilms tumor

Liver metastases at diagnosis

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

The liver is an infrequent site of metastases at diagnosis for patients with stage IV FH Wilms tumor, but it is the most common site after the lung. In 634 patients with stage IV FH Wilms tumor from the NWTS-4 and -5 studies, 96 (15%) presented with liver involvement.[239] In the AREN0533 study of 47 patients (14%) with FH Wilms tumor who presented with extrapulmonary metastases, there were 37 patients with isolated liver metastases and 10 patients with liver metastases in combination with other metastatic sites. Thirty-eight patients presented with lung and extrapulmonary sites. All patients were treated with regimen M and abdominal radiation therapy depending on local tumor stage. The 4-year EFS rate was 76%, and the OS rate was 89%. Only 2 patients had a resection of the liver metastases (both of whom also received liver radiation therapy). Of the patients who received liver radiation therapy (27 of 39), none relapsed in the liver.[279]

Sources: 239 · 279

The impact of liver metastases at diagnosis on patient care management has not been studied in a prospective manner. Most reported experiences come from single institutions and/or retrospective studies that do not include more modern surgical approaches or contemporary risk stratification parameters. In aggregate, there are not sufficient data to support liver metastases as an unfavorable site for metastatic disease, although there were some early SIOP studies that conflicted with this finding.[239,282-286]

Sources: 239 · 282 · 286

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment of stage IV Wilms tumor / Liver metastases at diagnosis

NWTS

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

A retrospective analysis of 742 patients with stage IV Wilms tumor who were treated on the NWTS-4 and -5 trials examined the outcomes of patients with and without lung metastases alone. The study also investigated survival outcomes for these patients according to whether they underwent a resection of their hepatic tumors.[239]

Sources: 239

Twenty-two patients underwent primary liver resections (18 wedge resections and 4 lobectomies). After chemotherapy and/or radiation therapy, 13 patients underwent liver resections (7 wedge resections, 5 lobectomies, and 1 trisegmentectomy).

Seventy-one patients (67%) did not undergo surgery for their liver disease. In 14 patients, the liver disease responded completely to chemotherapy alone.

Eighty-two patients received abdominal radiation therapy.

The EFS rate was 75% for patients with metastatic FH Wilms tumor. For patients with lung-only metastases (n = 513), the EFS rate was 76%. For patients with liver metastases without lung metastases (n = 34), the EFS rate was 76%. The EFS rate was 70% (n = 62) for patients with both liver and lung metastases, compared with 64% for patients (n = 25) with other sites of metastases. There were no significant differences between the stage IV groups of patients (P = .60).

The EFS rate was 86% for patients who underwent primary resection of the liver metastases (n = 22), compared with 68% for patients who did not have a primary resection of the liver metastases (P = .09).

No significant difference in EFS was observed for patients treated with chemotherapy alone compared with patients treated with chemotherapy and radiation therapy (P = .63). The EFS rates were 64% for patients who did not receive abdominal radiation therapy, 77% for patients who received abdominal radiation therapy without a boost, and 72% for patients who received abdominal radiation therapy with a boost (P = .05).

Adult patients comprised part of the study population (<10% were older than 12 years and 3% were older than 16 years).

Based on these data, the authors concluded that liver metastasis at diagnosis is not an independent adverse prognostic factor for patients with stage IV disease. They also suggested that there is no reason to perform hepatic resection in the up-front setting. These two studies occurred between the 1960s and 1990s. During this time, hepatic resection techniques and approaches changed based on a better understanding of the liver anatomy. Furthermore, contemporary risk stratification approaches that include tumor cytogenetics were not evaluated in these studies nor were more conventional radiation techniques such as IMRT, which has the potential to provide better protection to normal tissues.[287]

Sources: 287

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment of stage IV Wilms tumor / Liver metastases at diagnosis

SIOP

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

The SIOP/Gesellschaft für Pädiatrische Hämatologie und Onkologie (GPOH) group has recommended a more aggressive surgical approach. This recommendation was based on the reported outcomes of 29 patients treated on the SIOP93-01/GPOH and SIOP2001/GPOH trials that enrolled 1,365 patients between 1994 and 2004. Two of the patients had diffuse anaplasia.[283]

Sources: 283

The 5-year OS rate was 62.6% for patients with hepatic metastases, whereas the OS rate was 76.3% for all patients with stage IV disease. Within the group of patients with liver metastases, 14 did not undergo liver resections. Four of the patients (13%) responded to chemotherapy and were still alive at the time of the publication.

Fifteen patients underwent liver surgery (11 primary liver resections, 6 complete resections, and 5 incomplete resections). All six patients who had a complete resection survived.

As a result of these findings, the authors recommended an aggressive initial surgical approach for patients with liver disease. However, it is important to remember that SIOP patients receive preoperative chemotherapy before nephrectomy and/or resection of metastatic lesions.

The French cohort enrolled on the SIOP2001 trial included 131 patients with stage IV FH Wilms tumor. Of these patients, 18 (14%) had liver metastases at diagnosis, including 4 (3%) with isolated liver metastases.[286]

Sources: 286

The 5-year EFS rate was 83%, and the OS rate was 88% for this cohort of patients with liver metastases.

The authors concluded that liver involvement does not appear to be an adverse prognostic marker in patients with metastatic Wilms tumors, although there was a small number of patients in this study.

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment of stage IV Wilms tumor

Treatment of stage IV diffuse anaplastic Wilms tumor

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

In the AREN0321 (NCT00335556) study, the combination of vincristine and irinotecan (VI) was tested in an up-front window for patients with diffuse anaplastic Wilms tumor and measurable disease.[267][Level of evidence C2]

Sources: AREN0321 (NCT00335556) · 267 · Level of evidence C2

Fourteen patients with stage IV diffuse anaplastic Wilms tumor with measurable disease received the window therapy; one patient achieved a complete response (CR), ten patients achieved partial responses (PRs), and no patients had stable disease. This resulted in a CR and PR rate of 79%.

Patients who responded to VI in the window therapy had VI incorporated into their regimen (UH2).

Because of the observed cardiac/pulmonary toxicities encountered in this trial, the study was interrupted and amended with reduced doses of doxorubicin, cyclophosphamide, and etoposide (when combined with carboplatin).

Further study of the modified regimen is planned in patients with newly diagnosed diffuse anaplastic Wilms tumor.

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment of stage IV Wilms tumor

Treatment options under clinical evaluation

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

The following is an example of a national and/or institutional clinical trial that is currently being conducted:

AREN1921 (NCT04322318) (A Study of Combination Chemotherapy for Patients With Newly Diagnosed Diffuse Anaplastic Wilms Tumors and Relapsed Favorable-Histology Wilms Tumors): This clinical trial aims to improve survival by intensifying treatment for patients with diffuse anaplastic Wilms tumors. This trial will expand on the overall improvement observed with the revised UH1/UH2 regimen from the AREN0321 trial, which was modified along with the addition of vincristine/irinotecan.

Sources: AREN1921 (NCT04322318) · AREN0321

Health professional · Wilms Tumor / Treatment of Wilms Tumor

Treatment of stage V Wilms tumor and those predisposed to developing bilateral Wilms tumor

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Currently, there is not a standard approach for the treatment of stage V Wilms tumor (bilateral Wilms tumor at diagnosis) and those predisposed to developing bilateral Wilms tumor. However, for the first time, a prospective study of the treatment of patients with bilateral Wilms tumor has been completed and provides guidance for the approach.[176]

Sources: stage V Wilms tumor · 176

Management of a child with bilateral Wilms tumor is very challenging. The goals of therapy are to eradicate all tumor and to preserve as much normal renal tissue as possible, with the hope of decreasing the risk of chronic renal failure among these children.[288]

Sources: 288

Historically, based on the NWTS-4 and NWTS-5 trials and trials performed in Europe, patients with bilateral Wilms tumor have had a lower EFS and OS than have patients with localized Wilms tumor. The NWTS-4 study reported that the 8-year EFS rate for patients with bilateral FH Wilms tumor was 74%, and the OS rate was 89%; for patients with anaplastic histology, the EFS rate was 40%, and the OS rate was 45%.[204] The NWTS-5 study reported that the 4-year EFS rate for all bilateral Wilms tumor patients was 56%, and the OS rate was 81%; the 4-year EFS rates for patients with FH (65%), focal anaplastic histology (76%), and diffuse anaplastic histology (25%) were also reported.[110,183] The SIOP Renal Tumor Study Group reported the results of the SIOP2001 trial for the treatment of patients with bilateral Wilms tumor. Surgery was recommended after neoadjuvant chemotherapy, which consisted of dactinomycin and vincristine, with response-adapted intensification. In 174 patients with bilateral Wilms tumor, the 5-year EFS rate was 76.1%, and the OS rate was 88.1%. With a median follow-up of 7.4 years, 87% of patients retained normal renal function without a transplant.[289]

Sources: NWTS-5 · 204 · 110 · 183 · 289

Treatment options for stage V (bilateral) Wilms tumor include the following:

Preoperative chemotherapy and resection.

Sources: Preoperative chemotherapy and resection

Renal transplant.

Sources: Renal transplant

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment of stage V Wilms tumor and those predisposed to developing bilateral Wilms tumor

Preoperative chemotherapy and resection

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

For patients with bilateral Wilms tumor, the goal of therapy is to preserve as much renal tissue as possible without compromising overall outcome. This approach is used to avoid the late effect of end-stage renal disease, which can be caused by underlying germline genetic aberrations and treatment-related loss of functional renal tissue. End-stage renal disease occurs more frequently in patients with bilateral Wilms tumor (12% nonsyndromic) than in patients with unilateral Wilms tumor (<1%). Functional renal outcome is considerably better after bilateral nephron-sparing surgery than after other types of surgery.[176]

Sources: 176

Traditionally, patients have undergone bilateral renal biopsies, with staging of each kidney followed by preoperative chemotherapy. In the first prospective multi-institutional treatment trial (COG AREN0534 [NCT00945009]), pretreatment biopsies were not required if results of imaging tests were consistent with Wilms tumor.[176] This approach was taken because the bilateral occurrence of non-Wilms renal tumors is very low. Also, core-needle and wedge biopsies are not highly successful in identifying anaplasia in Wilms tumor.[174] In the setting of an unusual clinical situation, such as age older than 10 years or atypical imaging features, when a diagnosis other than Wilms should be considered, a tissue diagnosis is obtained.[176]

Sources: AREN0534 [NCT00945009] · 176 · 174 · 176

For patients who are treated with preoperative chemotherapy, the tumor pathology needs to be evaluated after 4 to 8 weeks. For patients not treated in a clinical trial, the ideal time to perform a biopsy or resection is unknown because minimal shrinkage may reflect chemotherapy-induced differentiation or anaplastic histology. A planned attempt at resection or biopsy of apparently unresectable tumor is undertaken no later than 12 weeks from diagnosis. Continuing therapy without evaluating tumor pathology in a patient with bilateral Wilms tumor may miss anaplastic histology or chemotherapy-induced differentiation (including rhabdomyomatous differentiation) and thus increase toxicity for the patient without providing additional benefit for tumor control. Anaplastic histology occurs in 10% of patients with bilateral Wilms tumor, and these tumors respond poorly to chemotherapy.[204]

Sources: 204

Once the diagnosis is confirmed, a complete resection is performed. Histological confirmation of the diagnosis is not straightforward. In a series of 27 patients from the NWTS-4 study, discordant pathology (unilateral anaplastic tumor) was seen in 20 cases (74%), which highlights the need to obtain tissue from both kidneys. Seven children who were later diagnosed with diffuse anaplastic tumors had core biopsies performed to establish the diagnosis; however, anaplasia was not found. Anaplasia was identified in only three of the nine patients when an open-wedge biopsy was performed and in seven of nine patients who had a partial or complete nephrectomy.[204]

Sources: 204

The decision to administer chemotherapy and/or radiation therapy after biopsy or a second-look operation is dependent on the tumor's response to initial therapy. More aggressive therapy is required for patients with inadequate response to initial therapy observed at the second procedure or in the setting of anaplasia.[216,290,291]

Sources: 216 · 290 · 291

End-stage renal disease is the most clinically significant morbidity in patients with bilateral Wilms tumor and can be caused by underlying germline genetic aberrations, as well as treatment-related loss of functional renal tissue. Long-term monitoring of renal function is required after treatment for bilateral disease.

Evidence (preoperative chemotherapy and resection for bilateral Wilms tumor):

The first prospective study in bilateral Wilms tumor (AREN0534 [NCT00945009]) aimed to improve EFS and OS while preserving renal tissue by intensifying preoperative chemotherapy (using three drugs—vincristine, dactinomycin, and doxorubicin), completing definitive surgery by 12 weeks from diagnosis, and modifying postoperative chemotherapy based on histological response.[176]; [292][Level of evidence C2]

Sources: AREN0534 [NCT00945009] · 176 · 292 · Level of evidence C2

The first prospective study in bilateral Wilms tumor (AREN0534 [NCT00945009]) aimed to improve EFS and OS while preserving renal tissue by intensifying preoperative chemotherapy (using three drugs—vincristine, dactinomycin, and doxorubicin), completing definitive surgery by 12 weeks from diagnosis, and modifying postoperative chemotherapy based on histological response.[176]; [292][Level of evidence C2]

For the arm that treated children with bilateral Wilms tumor, results showed that central review of imaging, surgical resection within 12 weeks of diagnosis, and response-based and histology-based postoperative therapy improved EFS and OS, when compared with the historical outcomes of children with bilateral Wilms tumor.

For the 180 patients with bilateral Wilms tumor, the 4-year EFS rate was 81% (95% confidence interval [CI], 74%–87%), and the OS rate was 95% (95% CI, 91%–99%). The above-described approach with risk assignment for treatment based on both staging and postoperative histopathology yielded excellent outcomes for patients with bilateral Wilms tumors but did not improve outcome for patients with diffuse anaplasia. Seven patients who had completely necrotic tumors had a 4-year EFS rate of 100%. Of 118 patients who had tumors with intermediate-risk histopathology, the 4-year EFS rate was 82% and the OS rate was 97%. Fourteen patients with blastemal-type tumors had a 4-year EFS rate of 79% and an OS rate of 93%. Patients who had complete necrosis were assigned to the low-risk category and those with blastemal-type histopathology to the high-risk category for subsequent treatments. For 18 patients who had diffuse anaplasia, the 4-year EFS rate was 61% and the OS rate was 72%. For seven patients who had focal anaplasia, the EFS rate was 71% and the OS rate was 100%.[292][Level of evidence C2] Because biopsy was not performed before treatment in this series, some of the patients enrolled may have had only nephrogenic rests and not a true Wilms tumor. This finding may have improved these survival figures over historical controls.

Sources: 292 · Level of evidence C2

Participants in the AREN0534 trial were followed for up to 10 years. The overall 8-year EFS rate was 75% (95% CI, 69%–83%), with a median follow-up of 8.6 years. The highest risk of an EFS event was immediately after diagnosis, with a declining rate over the following 2 years. Over 25% of first recurrences occurred more than 2 years after diagnosis. These late events tended to occur in year 3, with a smaller number of events after year 6. The risk of late recurrences was higher in female patients, patients with anaplastic histology tumors, and patients with negative lymph nodes or margins. Distant relapses in the lungs, liver, or abdomen tended to occur early, while relapses after 2 years were usually in kidney tissue (80% of recurrences). Based on this study, the investigators suggested that observation of patients with bilateral Wilms tumor continue beyond 4 years after diagnosis.[293]

Sources: 293

One of the aims of the study was that 75% of patients undergo definitive surgery by 12 weeks. After induction chemotherapy, 163 of 189 patients (84%) underwent definitive surgical treatment in at least one kidney by 12 weeks, and 39% of patients retained parts of both kidneys.

Chemotherapy after surgery was tailored according to histological response. The 4-year EFS rate was 84.1% for FH tumors, 58.2% for anaplastic histology tumors, and 82% for blastemal-type tumors.

Because of the higher risk of renal failure in patients with bilateral Wilms tumor than in patients with unilateral Wilms tumor, one of the goals of the study was that 50% of the patients undergo bilateral nephron-sparing surgery. This threshold was not met, with only 39% of patients successfully treated with bilateral nephron-sparing surgery.

Based on the above study, the recommendation was to continue with three-drug preoperative chemotherapy for 6 to 12 weeks followed by nephron-sparing surgery whenever possible. After resection, postoperative therapy is based on the histology of the resected specimen. The disappointing use of nephron-sparing surgery in this study may have been because of the level of experience of the surgeons in this multi-institutional study.

Outcomes of patients with anaplasia and bilateral Wilms tumor were examined in the AREN0534 study. Twenty-seven patients were enrolled (17 had diffuse anaplasia and 10 had focal anaplasia). Twenty-six patients had bilateral disease. One patient presented with unilateral disease (within the patient's solitary kidney).[294]

Sources: 294

Outcomes of patients with anaplasia and bilateral Wilms tumor were examined in the AREN0534 study. Twenty-seven patients were enrolled (17 had diffuse anaplasia and 10 had focal anaplasia). Twenty-six patients had bilateral disease. One patient presented with unilateral disease (within the patient's solitary kidney).[294]

Twenty-one of the 26 patients with bilateral disease had discordant pathology. This suggests that if a biopsy is needed, both kidneys should be sampled.

The 4-year and 8-year EFS rates were both 53% for patients with diffuse anaplasia. The 4-year EFS rate was 80%, and the 8-year EFS rate was 70% for patients with focal anaplasia.

The EFS and OS did not differ by margin status.

All children who died experienced prior relapse or progression within 18 months of study enrollment.

In a retrospective review of 49 patients with Wilms tumor who received preoperative therapy according to the SIOP-93-01 (NCT00003804) guidelines, the timing of surgery was determined when there was no longer imaging evidence of tumor regression. The mean treatment duration was 80 days before renal-sparing surgery.[295]

Sources: SIOP-93-01 (NCT00003804) · 295

In a retrospective review of 49 patients with Wilms tumor who received preoperative therapy according to the SIOP-93-01 (NCT00003804) guidelines, the timing of surgery was determined when there was no longer imaging evidence of tumor regression. The mean treatment duration was 80 days before renal-sparing surgery.[295]

The 5-year EFS rate was 83.4%, and the OS rate was 89.5%.

All but one of the patients had renal-sparing surgery in at least one kidney.

Despite the good survival, 14% of the patients developed end-stage renal disease.

In a retrospective review from St. Jude Children's Research Hospital, investigators described their experience with preoperative chemotherapy followed by renal-sparing procedures in children with bilateral FH Wilms tumor.[296]

Sources: 296

In a retrospective review from St. Jude Children's Research Hospital, investigators described their experience with preoperative chemotherapy followed by renal-sparing procedures in children with bilateral FH Wilms tumor.[296]

In one series, 39 of 42 patients with bilateral FH Wilms tumor underwent successful bilateral renal-sparing procedures after receiving preoperative chemotherapy. Three patients underwent unilateral nephrectomy with contralateral nephron-sparing surgery. Three patients required early (within 4 months) repeat nephron-sparing surgery for residual tumor. In the long term, seven patients had local tumor recurrence, and three patients had intestinal obstruction.

The OS rate was 86% (mean follow-up, 4.1 years). Of the six patients who died, five had diffuse anaplastic histology.

All of the patients had an estimated glomerular filtration rate of more than 60 mL/min/1.73m2 at the last follow-up; none of the patients developed end-stage renal disease.

The authors concluded that bilateral renal-sparing surgery is almost always feasible and can be done safely with good oncologic outcomes in patients with synchronous, bilateral Wilms tumor. It should be considered even if preoperative imaging studies suggest that the lesions are unresectable. Sparing of renal parenchyma is likely to help preserve renal function in children who are at significant risk of chronic renal insufficiency. Careful long-term follow-up is required to fully assess the potential progression of renal dysfunction.

A follow-up review of these patients revealed the following: 8 of 36 patients underwent repeat nephron-sparing surgery, and an additional two patients required a third nephron-sparing surgery. Six of these patients were alive without disease at the 4.5-year follow-up. The two patients who died had blastemal-predominant histology.[297]

Sources: 297

For information about recurrent disease, see the Treatment and outcomes of recurrent Wilms tumor section.

Sources: Treatment and outcomes of recurrent Wilms tumor

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment of stage V Wilms tumor and those predisposed to developing bilateral Wilms tumor

Treatment of patients with multicentric or bilaterally predisposed unilateral Wilms tumors

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Based on an identified subpopulation of patients with Wilms tumor who are at risk for metachronous disease, coupled with an increased risk of end-stage renal disease, the COG conducted the largest prospective study (AREN0534 [NCT00945009]) of these patients. The goal of this study was to preserve renal tissue while maintaining excellent overall outcomes.[4,92]

Sources: AREN0534 [NCT00945009] · 4 · 92

Patients were identified by the treating institution as having a predisposition syndrome. Induction chemotherapy was determined by the presence of localized or metastatic disease found on imaging (and histology if a biopsy had been performed) at the time of diagnosis. Surgery, including renal-sparing surgery, was based on the radiographic response at 6 or 12 weeks, and additional chemotherapy was determined by histology. Patients with favorable histology and stage III or IV disease or any patient with anaplasia received radiation therapy.[147][Level of evidence C1]

Sources: 147 · Level of evidence C1

Thirty-four patients were enrolled with the following underlying conditions: Beckwith-Wiedemann syndrome (n = 9), hemihypertrophy (n = 9), multicentric tumors (n = 10), WAGR syndrome (n = 2), solitary kidney (n = 2), Denys-Drash syndrome (n = 1), and Simpson-Golabi-Behmel syndrome (n = 1).

The 4-year EFS and OS rates were 94% and 100%, respectively, with a median follow-up of 4.49 years. Two patients relapsed (one in the tumor bed and one in the abdomen); none of the deaths occurred during induction.

Prenephrectomy chemotherapy facilitated renal preservation in 22 of 34 patients (65%). Eleven partial nephrectomies were performed after two cycles of chemotherapy, and nine partial nephrectomies were performed after four cycles of chemotherapy. Two of the tumors completely resolved after treatment with chemotherapy and required no subsequent surgery.

There were 22 patients with a known predisposition syndrome for which routine ultrasonography screening would have been expected. Sixteen of these patients had stage I disease, three had stage II disease, and three had stage III disease. Thirteen of the tumors were detected through routine ultrasonography.

These results suggest that a standardized treatment approach that includes preoperative chemotherapy, surgical resection within 6 to 12 weeks, and histology-based postoperative chemotherapy results in excellent EFS, OS, and preservation of renal parenchyma.

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment of stage V Wilms tumor and those predisposed to developing bilateral Wilms tumor / Treatment of patients with multicentric or bilaterally predisposed unilateral Wilms tumors

WAGR syndrome and Wilms tumor outcomes

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

The comprehensive International WAGR Syndrome Association survey was used to analyze tumor characteristics, treatment, congenital risk factors, and kidney function in children with WAGR syndrome and Wilms tumors. Of 145 children with WAGR syndrome, 64 developed Wilms tumors (44%).[18]

Sources: 18

Of patients with Wilms tumors, three had relapsed disease and one died. Most patients presented with low-stage disease (stages I–II) and favorable histology.

Chronic kidney disease developed in five children with WAGR syndrome and no Wilms tumors (6.2%) and in 34 children with WAGR syndrome and Wilms tumors (53.1%). Two children with Wilms tumors required hemodialysis, and one child underwent a kidney transplant.

Compared with total nephrectomy, nephron-sparing surgery appeared protective against chronic kidney disease, but it was only used in 37.5% of cases.

By univariate analysis, chronic kidney disease at any stage was associated with complete nephrectomy (P < .0001), chemotherapy duration longer than 12 months, and three-drug therapy. By multivariate analysis, prior nephrectomy was the only significant variable (P = .0002).

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment of stage V Wilms tumor and those predisposed to developing bilateral Wilms tumor

Renal transplant

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Renal transplant for children with stage V Wilms tumor is usually delayed until 1 to 2 years have passed without evidence of malignancy because most relapses occur within 2 years of diagnosis.[298] Similarly, renal transplant for children with Denys-Drash syndrome and Wilms tumor, all of whom require bilateral nephrectomy, is generally delayed 1 to 2 years after completion of initial treatment.[298]

Sources: 298 · 298

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment of stage V Wilms tumor and those predisposed to developing bilateral Wilms tumor

Treatment options under clinical evaluation

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

Health professional · Wilms Tumor / Treatment of Wilms Tumor

Treatment and outcomes of recurrent Wilms tumor

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Patients with recurrent Wilms tumor should consider enrolling in phase I and phase II clinical trials. Other treatment options for recurrent Wilms tumor are discussed below.

Palliative care remains a central focus of management regardless of whether disease-directed therapy is pursued at the time of progression. This ensures that quality of life is maximized while attempting to reduce symptoms and stress related to the terminal illness.

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment and outcomes of recurrent Wilms tumor

Prognosis, prognostic factors, and risk categories for recurrent Wilms tumor

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Approximately 15% of patients with FH Wilms tumor and 50% of patients with anaplastic histology Wilms tumor experience recurrence.[180] The most common site of relapse is lung, followed by abdomen/flank and liver. Recurrence in the brain (0.5%) or bone is rare in children with Wilms tumor.[299,300] Historically, the salvage rate for patients with recurrent FH Wilms tumor was 25% to 40%. As a result of modern treatment combinations, the outcome after recurrence has improved to up to 60%.[301-303]

Sources: 180 · 299 · 300 · 301 · 303

About 95% of first Wilms tumor recurrences occur within 2 years of initial diagnosis. Relapse more than 5 years after diagnosis is considered a late recurrence and is rare. In the largest retrospective study of more than 1,300 children enrolled in various Wilms tumor trials, the median time to late recurrence after first recurrence was 13 years (range, 5–17 years).[304,305]

Sources: 304 · 305

A number of potential prognostic features influencing postrecurrence outcomes have been analyzed, but it is difficult to determine whether these factors are independent of each other. Also, the following prognostic factors appear to be changing as therapy for primary and recurrent Wilms tumor evolves:

Anaplastic histology.[306]

Sources: 306

Advanced tumor stage.[306]

Sources: 306

Sex. Sex was predictive of outcome, with males faring worse than females.[301,307]

Sources: 301 · 307

The NWTS-5 trial showed that time to recurrence and site of recurrence are no longer prognostically significant.[301,307] However, in a SIOP study, patients who experienced a pulmonary relapse within 12 months of diagnosis had a poorer prognosis (5-year OS rate, 47%) than did patients who experienced a pulmonary relapse 12 months or more after diagnosis (5-year OS rate, 75%).[308]

Sources: 301 · 307 · 308

Based on these results, the following three risk categories have been identified:

Standard risk: Patients with FH Wilms tumor who relapse after therapy with only vincristine and/or dactinomycin. These patients account for approximately 30% of recurrences and are expected to have EFS rates of 70% to 80%.[302]

Sources: 302

High risk: Patients with FH Wilms tumor who relapse after therapy with three or more agents. These patients account for 45% to 50% of children with Wilms tumor who relapse and have survival rates in the 40% to 50% range.[302]

Sources: 302

Very high risk: Patients with recurrent anaplastic or blastemal-predominant Wilms tumor. These patients account for 10% to 15% of all Wilms tumor relapses and are expected to have survival rates in the 10% range.[183,302]

Sources: 183 · 302

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment and outcomes of recurrent Wilms tumor

Treatment of standard-risk relapsed Wilms tumor

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

In children who had small stage I Wilms tumor and were treated with surgery alone, the EFS rate was 84%. All but one child who relapsed was salvaged with treatment tailored to the site of recurrence.[184,307]

Sources: 184 · 307

Successful retreatment can be accomplished for Wilms tumor patients whose initial therapy consisted of immediate nephrectomy followed by chemotherapy with vincristine and dactinomycin and who relapse.

Treatment options for standard-risk relapsed Wilms tumor include the following:

Surgery, radiation therapy, and chemotherapy.

Sources: Surgery, radiation therapy, and chemotherapy

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment and outcomes of recurrent Wilms tumor / Treatment of standard-risk relapsed Wilms tumor

Surgery, radiation therapy, and chemotherapy

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Evidence (surgery, radiation therapy, and chemotherapy):

Fifty-eight patients were treated on the NWTS-5 relapse protocol with surgical excision when feasible, radiation therapy, and courses of vincristine, doxorubicin, and cyclophosphamide alternating with etoposide and cyclophosphamide.[307]

Sources: NWTS-5 · 307

Fifty-eight patients were treated on the NWTS-5 relapse protocol with surgical excision when feasible, radiation therapy, and courses of vincristine, doxorubicin, and cyclophosphamide alternating with etoposide and cyclophosphamide.[307]

The 4-year EFS rate after relapse was 71%, and the OS rate was 82%.

For patients whose site of relapse was only the lungs, the 4-year EFS rate was 68%, and the OS rate was 81%.

The SIOP Renal Tumor Study Group (SIOP-RTSG) analyzed the outcomes of low- and intermediate-risk patients (n = 109) who relapsed after treatment with vincristine and dactinomycin for primary Wilms tumor from their SIOP 93-01 and SIOP 2001 studies.[309][Level of evidence: C1]

Sources: 309 · Level of evidence: C1

The SIOP Renal Tumor Study Group (SIOP-RTSG) analyzed the outcomes of low- and intermediate-risk patients (n = 109) who relapsed after treatment with vincristine and dactinomycin for primary Wilms tumor from their SIOP 93-01 and SIOP 2001 studies.[309][Level of evidence: C1]

The postrelapse 5-year EFS rate was 72.3%, and the OS rate was 79.3%.

Patients treated with vincristine, dactinomycin, and doxorubicin (VAD) did not fare worse than patients treated with more intensive therapies (such as cyclophosphamide, carboplatin, etoposide, and doxorubicin or ifosfamide, carboplatin, and etoposide [ICE] backbones; HR for EFS, 0.611; HR for OS, 0.438).

There was no survival difference between patients treated with VAD compared with ICE-based regimens.

The type of alkylating agent (ifosfamide or cyclophosphamide) used in more intensive treatment regimens did not affect survival rates.

Incorporation of high-dose hematopoietic stem cell transplant (HSCT) to consolidate relapse treatment did not improve the outcome for standard-risk relapse patients.

Future studies may be able to identify patients who may benefit from VAD treatment rather than more intensive treatment with combination chemotherapy including cyclophosphamide, carboplatin, etoposide, and doxorubicin.

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment and outcomes of recurrent Wilms tumor

Treatment of high-risk and very high-risk relapsed Wilms tumor

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Treatment options for high-risk and very high-risk relapsed Wilms tumor include the following:

Chemotherapy, surgery, and/or radiation therapy.

Sources: Chemotherapy, surgery, and/or radiation therapy

HSCT.

Sources: HSCT

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment and outcomes of recurrent Wilms tumor / Treatment of high-risk and very high-risk relapsed Wilms tumor

Chemotherapy, surgery, and/or radiation therapy

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Evidence (chemotherapy, surgery, and/or radiation therapy):

Approximately 50% of unilateral Wilms tumor patients who relapse or progress after initial treatment with vincristine, dactinomycin, and doxorubicin and radiation therapy can be successfully re-treated. Sixty patients with unilateral Wilms tumor were treated on the NWTS-5 relapse protocol with alternating courses of cyclophosphamide/etoposide and carboplatin/etoposide, surgery, and radiation therapy.[301][Level of evidence B4]

Sources: NWTS-5 · 301 · Level of evidence B4

Approximately 50% of unilateral Wilms tumor patients who relapse or progress after initial treatment with vincristine, dactinomycin, and doxorubicin and radiation therapy can be successfully re-treated. Sixty patients with unilateral Wilms tumor were treated on the NWTS-5 relapse protocol with alternating courses of cyclophosphamide/etoposide and carboplatin/etoposide, surgery, and radiation therapy.[301][Level of evidence B4]

The 4-year EFS rate for patients with high-risk Wilms tumor was 42%, and the OS rate was 48%.

High-risk patients who relapsed in the lungs only had a 4-year EFS rate of 49% and an OS rate of 53%.

Patients with stage II, stage III, and stage IV anaplastic tumors at diagnosis have a very poor prognosis upon recurrence.[183] The combination of ifosfamide, etoposide, and carboplatin demonstrated activity in this group of patients, but significant hematologic toxic effects have been observed.[310]

Sources: 183 · 310

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment and outcomes of recurrent Wilms tumor / Treatment of high-risk and very high-risk relapsed Wilms tumor

HSCT

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

High-dose chemotherapy followed by autologous HSCT has been used for recurrent high-risk patients.[311,312]; [313,314][Level of evidence C1]

Sources: 311 · 312 · 313 · 314 · Level of evidence C1

Evidence (HSCT):

Investigators used the European Blood and Marrow Transplantation Registry to examine the outcomes of children with Wilms tumor (n = 69) who received high-dose chemotherapy with autologous HSCT as consolidation during first or second remission. Different high-dose chemotherapy regimens were used, containing either melphalan (n = 34) or thiotepa (n = 14).[315][Level of evidence C1]

Sources: 315 · Level of evidence C1

Investigators used the European Blood and Marrow Transplantation Registry to examine the outcomes of children with Wilms tumor (n = 69) who received high-dose chemotherapy with autologous HSCT as consolidation during first or second remission. Different high-dose chemotherapy regimens were used, containing either melphalan (n = 34) or thiotepa (n = 14).[315][Level of evidence C1]

The 5-year OS and EFS probabilities were 0.67 (± 0.06) and 0.63 (± 0.06), respectively (median observation time, 7.8 years).

Children who underwent transplant in first remission had 5-year EFS and OS probabilities of 0.69 and 0.72, respectively.

The use of melphalan alone for high-dose chemotherapy led to noninferior survival rates, compared with other drugs or drug combinations, and to better engraftment, compared with thiotepa-containing regimens.

Similar outcome results were reported in a series of 54 patients with Wilms tumor who received high-dose chemotherapy with autologous stem cell rescue (first-line therapy, n = 13; recurrence therapy, n = 41).[314][Level of evidence C1]

Sources: 314 · Level of evidence C1

Similar outcome results were reported in a series of 54 patients with Wilms tumor who received high-dose chemotherapy with autologous stem cell rescue (first-line therapy, n = 13; recurrence therapy, n = 41).[314][Level of evidence C1]

For patients treated at the time of recurrence, the 5-year EFS and OS rates were 57% and 69%, respectively (median follow-up, 7 years).

The outcomes of 253 patients with relapsed Wilms tumor who received high-dose chemotherapy followed by autologous HSCT between 1990 and 2013 were reported to and reviewed by the Center for International Blood and Marrow Transplantation Research.[316]

Sources: 316

The outcomes of 253 patients with relapsed Wilms tumor who received high-dose chemotherapy followed by autologous HSCT between 1990 and 2013 were reported to and reviewed by the Center for International Blood and Marrow Transplantation Research.[316]

The 5-year estimate for EFS was 36%, and the 5-year estimate for OS was 45%.

Relapse of primary disease was the cause of death in 81% of the population.

No randomized trials comparing chemotherapy and transplant have been reported, and case series suffer from selection bias.

Patients in whom such salvage attempts fail should be offered treatment on phase I or phase II clinical trials.

Health professional · Wilms Tumor / Treatment of Wilms Tumor / Treatment and outcomes of recurrent Wilms tumor

Treatment options under clinical evaluation for recurrent Wilms tumor

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

The following is an example of a national and/or institutional clinical trial that is currently being conducted:

AREN1921 (NCT04322318) (A Study of Combination Chemotherapy for Patients With Newly Diagnosed Diffuse Anaplastic Wilms Tumor and Relapsed Favorable-Histology [FH] Wilms Tumor): Patients with standard-risk relapsed FH Wilms tumor (pretreated with two drugs) will receive chemotherapy consisting of vincristine/doxorubicin/cyclophosphamide alternating with cyclophosphamide/carboplatin/etoposide alternating with vincristine/irinotecan. Patients with high-risk relapsed FH Wilms tumor (pretreated with three drugs) and very high-risk relapsed FH Wilms tumor (pretreated with ≥ four drugs) will be treated with cyclophosphamide and topotecan added to a backbone of ifosfamide, carboplatin, and etoposide.

Sources: AREN1921 (NCT04322318)

Health professional · Wilms Tumor / Treatment of Wilms Tumor

Follow-up after treatment

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

For patients who have completed therapy for Wilms tumor and exhibit features consistent with genetic predisposition, such as bilateral Wilms tumor, screening involves renal ultrasonography examination every 3 months for metachronous tumors during the risk period for that particular syndrome (5 years for WT1-related syndromes; 8 years for Beckwith-Wiedemann syndrome).

Health professional · Wilms Tumor / Treatment of Wilms Tumor

Late effects after Wilms tumor therapy

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Children treated for Wilms tumor are at increased risk of developing the following:

Premature mortality after Wilms tumor diagnosis. Long-term morbidity and mortality among unilateral, nonsyndromic Wilms tumor survivors were evaluated in the Childhood Cancer Survivor Study (CCSS). Among 2,008 survivors, 142 deaths occurred (standardized mortality ratio [SMR], 2.9 [95% CI, 2.5–3.5]; 35-year cumulative incidence of death, 7.8% [95% CI, 6.3%–9.2%]). The most frequent causes of death were subsequent malignant neoplasms (SMNs) (n = 42), Wilms tumor relapse (n = 30), and cardiac related (n = 9). Survivors who were treated with vincristine and dactinomycin (VA) alone had comparable risk for all-cause mortality (SMR,1.0) and health-related late mortality (SMR, 1.5) relative to the general population.[317]

Sources: 317

Chronic health conditions. Findings from the same CCSS study are as follows:[317]

Sources: 317

Chronic health conditions. Findings from the same CCSS study are as follows:[317]

Of unilateral Wilms tumor survivors (n = 2,008), the 35-year cumulative incidence of any grades 3 to 5 chronic health condition was 34.1% among Wilms tumor survivors and 14.8% among siblings.

Survivors treated with VA alone had a modestly increased risk of developing grades 3 to 5 chronic health conditions compared with siblings (RR, 1.5).

Risks of grades 3 to 5 chronic health conditions, including intestinal obstruction (8.1%), kidney failure (2.4%), premature ovarian insufficiency (7.3%) and heart failure (4.0%), increased by treatment intensity in a dose-dependent manner and by exposure to doxorubicin and/or radiation therapy. This risk was most pronounced among survivors with high-risk disease, including those with early relapse (<5 years).

Compared with siblings, survivors treated with VA showed a higher risk of intestinal obstruction (RR, 9.4) and kidney failure (RR, 11.9) but the magnitude of the risk was lower than that for more intensive treatment groups.

Both whole-lung and whole-abdomen radiation therapy were associated with increased risks of SMNs, heart failure, and intestinal obstruction, and the magnitude of risk increased with rising doses.

Whole-abdomen or flank radiation therapy higher than 20 Gy was associated with an increased risk of intestinal obstruction compared with no radiation therapy, whereas radiation therapy doses of 20 Gy or less were not associated with any chronic health condition.

SMNs.[318,319] In the CCSS study of Wilms tumor survivors (n = 2,008), 82 developed SMNs (standardized incidence ratio [SIR], 4.1), representing a cumulative incidence rate of 6.1%. Breast (SIR, 6.9), thyroid (SIR, 4.7) and intestinal/colorectal (SIR, 12.0) were the most frequently reported cancers.[317] The cumulative incidence of invasive breast cancer in Wilms tumor survivors who had received pulmonary radiation for metastatic Wilms tumor is nearly 15% by age 40 years.[320]

Sources: 318 · 319 · 317 · 320

Congestive heart failure. The risk of congestive heart failure is influenced by dose of doxorubicin received, radiation to the heart, and female sex.[321] CCSS investigators reported that cumulative doxorubicin doses of 250 mg/m2 or higher were associated with a nearly 5-fold rate of development of heart failure, compared with no doxorubicin exposure.[317]

Sources: 321 · 317

Infertility for patients who received whole-abdomen irradiation and/or cyclophosphamide.[322,323] The 35-year cumulative incidence rate of premature ovarian insufficiency was 7.3%. Whole-abdomen radiation therapy was associated with an increased risk of premature ovarian insufficiency, with a greater risk with increasing dose (≤20 Gy: RR, 13.1; >20 Gy: RR, 36.5).[317] Female survivors of Wilms tumor diagnosed before age 40 years from a St. Jude Lifetime Cohort Study experienced increased premature ovarian insufficiency compared with controls (9.3% vs. 0.6%; P < .01), likely because of abdominal irradiation that exposed the ovaries. None of the females exposed to hemiabdominal radiation therapy experienced premature ovarian insufficiency.[319]

Sources: 322 · 323 · 317 · 319

Complications of pregnancy.[324] One study examined the effects of radiation therapy to the abdomen (partial or whole abdomen) on pregnancy and pregnancy outcomes in patients with a history of Wilms tumor. The investigators reviewed hypertension complicating pregnancy, early or threatened labor, malposition of the fetus, premature rupture of membranes, obstructed labor, abnormality of forces of labor, and umbilical cord complications. There were 1,021 pregnancies (with a duration of 20 weeks or longer), including 955 live births, from which there were 700 sets of maternal and offspring medical records. Female survivors of Wilms tumor who received radiation therapy are at an increased risk of hypertension complicating pregnancy, early or threatened labor, and fetal malposition. The offspring of these patients were more likely to be premature and have low birth weights.[324] For more information, see the Reproduction section in Late Effects of Treatment for Childhood Cancer.

Sources: 324 · 324 · Reproduction

Late kidney failure. Based on the CCSS study, the cumulative incidence of late kidney failure among survivors was 2.4% (approximately a 10-fold increased rate relative to siblings). No single chemotherapy or radiation therapy–related exposure was associated with kidney failure, which suggests that nephrectomy may be the primary risk factor.[317] Rates of late kidney failure increase with advancing age. This finding highlights the importance of long-term monitoring of kidney function in these patients, particularly when the patients have other comorbidities. The cumulative incidence of end-stage renal disease caused by chronic renal failure at 20 years from diagnosis of Wilms tumor is 3.1% for patients with bilateral Wilms tumor.[213]

Sources: 317 · 213

Neurocognitive impairment. Among 264 long-term Wilms tumor survivors participating in a St. Jude Lifetime Cohort Study who completed neurocognitive testing, 19.7% had grades 2 to 3 executive function impairment, compared with 12% of controls (P < .01). In survivors, processing speed (19.7% vs. 8.4%) and memory (20.9% vs. 9.9%) showed a higher prevalence of moderate to severe impairments, compared with controls (P < .01). Only impairments in processing speed were associated with the presence of grades 2 to 4 cardiovascular disease.[319]

Sources: 319

Physical performance. In the CCSS study, survivors were more likely to report poor physical functioning (OR, 2.9) than siblings.[317] In a St. Jude Lifetime Cohort Study, 270 long-term Wilms tumor survivors completed function testing and were observed to have excess impairments in aerobic function, mobility, strength, endurance and flexibility, compared with controls. There were no clear associations between these outcomes and treatment exposures.[319]

Sources: 317 · 319

Late renal effects in patients with Wilms and underlying genetic abnormalities include the following:

Children with WAGR syndrome or other germline WT1 pathogenic variants are monitored throughout their lives because they are at increased risk of developing hypertension, nephropathy, and renal failure.[213]

Sources: 213

Patients with Wilms tumor and aniridia without genitourinary abnormalities are at lower risk but are monitored for nephropathy or renal failure.[325]

Sources: 325

Children with Wilms tumor and any genitourinary anomalies are also at increased risk of late renal failure and are monitored. Features associated with germline WT1 pathogenic variants that increase the risk of developing renal failure include the following:[213]

Sources: 213

Children with Wilms tumor and any genitourinary anomalies are also at increased risk of late renal failure and are monitored. Features associated with germline WT1 pathogenic variants that increase the risk of developing renal failure include the following:[213]

Stromal predominant histology.

Bilateral disease.

Intralobar nephrogenic rests.

Wilms tumor diagnosed before age 2 years.

For a full discussion of the late effects of cancer treatment in children and adolescents, see Late Effects of Treatment for Childhood Cancer.

Sources: Late Effects of Treatment for Childhood Cancer

Health professional · Renal Cell Carcinoma (RCC)

Treatment of RCC

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Survival of patients with RCC is affected by stage of disease at presentation and the completeness of resection at radical nephrectomy. In a COG prospective clinical trial of patients with newly diagnosed RCC, 68 patients (aged <30 years) were enrolled over a 6-year period. Complete surgical resection was attempted in all patients, regardless of the stage of their disease. Eight patients who had an incomplete surgical resection received chemotherapy. The 4-year event-free survival (EFS) rate was 80.2%, and the 4-year OS rate was 84.8%. For the 16 patients with N1M0 disease who underwent complete resection and no adjuvant therapy, the 4-year EFS and OS rates were 87.5% and 87.1%, respectively.[53][Level of evidence C1]

Sources: 53 · Level of evidence C1

Standard treatment options for RCC include the following:

Radical nephrectomy with lymph node sampling.

Sources: Radical nephrectomy with lymph node sampling

Renal-sparing surgery with lymph node sampling.

Sources: Renal-sparing surgery with lymph node sampling

Health professional · Renal Cell Carcinoma (RCC) / Treatment of RCC

Radical nephrectomy with lymph node sampling

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

The primary treatment for RCC includes total surgical removal of the kidney and associated lymph nodes.[34]

Sources: 34

Pediatric patients with translocation-positive RCC often have a better outcome than adult patients, which is generally attributed to a smaller percentage of distant metastasis in pediatric patients.[41] In younger patients, the disease is often managed with surgery alone. Of three pediatric patients (aged 3–12 years) in one study, two had previously received chemotherapy to treat retinoblastoma and neuroblastoma. All three patients underwent surgery only and remained disease free. These patients had a lower copy-number burden than the adults in the series.[37][Level of evidence C1]

Sources: 41 · 37 · Level of evidence C1

Health professional · Renal Cell Carcinoma (RCC) / Treatment of RCC

Renal-sparing surgery with lymph node sampling

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Renal-sparing surgery may be considered for carefully selected patients with low-volume localized disease. In two small series, patients who had partial nephrectomies seemed to have outcomes equivalent to those who had radical nephrectomies.[34]

Sources: 34

Health professional · Renal Cell Carcinoma (RCC) / Treatment of RCC

Other approaches

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

As with adult RCC, there is no standard treatment for unresectable metastatic disease in children. The response to radiation therapy is poor, and chemotherapy is not effective. Immunotherapy with agents such as interferon-alpha and interleukin-2 may have some effect on cancer control.[54,55] Spontaneous regression of pulmonary metastasis rarely occurs with resection of the primary tumor.

Sources: 54 · 55

Several targeted therapies (e.g., sorafenib, sunitinib, bevacizumab, temsirolimus, pazopanib, axitinib, and everolimus) have been approved for use in adults with RCC. The SIOP-Renal Tumor Study Group (RTSG) retrospectively reported their experience of 31 patients (aged 0–18 years) with RCC, 21 of whom had translocation-positive tumors. Sunitinib was often administered as the first choice (recommended in the SIOP-RTSG 2016 protocol) and predominantly resulted in stable disease (53%). Overall, 15 of 31 patients died of their disease.[56] Case reports of pediatric and adolescent patients with TFE3 translocation–positive RCC suggest responsiveness to multiple tyrosine kinase inhibitors.[35,57,58]; [59][Level of evidence C1] Disease regression and improvement in symptoms have been reported with the use of cabozantinib in pediatric patients with translocation-positive RCC expressing MET.[60] Any RCC that is positive for TFE3 and lacks a translocation should be tested for ALK expression and translocation. Recognition of this subtype may lead to consideration of ALK inhibitor therapy.[45]

Sources: 56 · 35 · 57 · 58 · 59 · Level of evidence C1 · 60 · 45

For more information about the use of targeted therapies, see Renal Cell Cancer Treatment.

Sources: Renal Cell Cancer Treatment

Health professional · Renal Cell Carcinoma (RCC)

Treatment Options Under Clinical Evaluation for RCC

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

Health professional · Rhabdoid Tumors of the Kidney

Treatment of Rhabdoid Tumor of the Kidney

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Because of the relative rarity of this tumor, all patients with rhabdoid tumor of the kidney should consider joining a clinical trial. Treatment planning by a multidisciplinary team of pediatric cancer specialists (surgeon or urologist, radiation oncologist, and oncologist) with experience treating renal tumors is required to determine and implement optimal treatment.

There are no standard treatment options for rhabdoid tumor of the kidney.[24]

Sources: 24

The following results have been observed in studies of rhabdoid tumor of the kidney:

In the Children's Oncology Group AREN0321 (NCT00335556) study, patients with rhabdoid tumor of the kidney or malignant rhabdoid tumor were treated with regimen UH1 or dose-reduced revised UH1, which included alternating three-drug combinations (vincristine/doxorubicin/cyclophosphamide and carboplatin/cyclophosphamide/etoposide). Revised UH1 was used to decrease the toxicity from UH1. This trial included a window therapy study to evaluate the efficacy of vincristine/irinotecan. Results from this trial were compared with those from the NWTS-5 trial (regimen included carboplatin/etoposide alternating with cyclophosphamide [regimen RTK]).[25]

Sources: AREN0321 (NCT00335556) · NWTS-5 · 25

In the Children's Oncology Group AREN0321 (NCT00335556) study, patients with rhabdoid tumor of the kidney or malignant rhabdoid tumor were treated with regimen UH1 or dose-reduced revised UH1, which included alternating three-drug combinations (vincristine/doxorubicin/cyclophosphamide and carboplatin/cyclophosphamide/etoposide). Revised UH1 was used to decrease the toxicity from UH1. This trial included a window therapy study to evaluate the efficacy of vincristine/irinotecan. Results from this trial were compared with those from the NWTS-5 trial (regimen included carboplatin/etoposide alternating with cyclophosphamide [regimen RTK]).[25]

Patients treated in the AREN0321 study had significantly improved EFS and OS, compared with those treated in the NWTS-5 trial (4-year EFS rate, 23.1% vs. 16.7%; P = .020; 4-year OS rate, 30.6% vs. 20.0%; P = .014).

Improvement in outcome was mostly driven by patients with stage I/II disease. Patients with stage I/II disease treated in AREN0321 had an improved 4-year EFS rate, compared with patients treated in NWTS-5 (83.3% vs. 50.0%; HR, 0.24). Similarly, for these patients, the OS rate was 100% in AREN0321, compared with 50.0% in NWTS-5 (P = .03). Among patients with stage III/IV disease, there was no difference in EFS or OS between the two studies. Patients with stage III/IV disease achieved long-term EFS rates of 12% to 13% (HR, 0.80) and 4-year OS rates of 17% to 18% in both cohorts (HR, 0.80).

In AREN0321, all three patients who received the window therapy had progressive disease, leading to closure of the window therapy study for rhabdoid tumor of the kidney and malignant rhabdoid tumor.

When studies were pooled, there was no difference in outcomes based on tumor location (renal vs. extrarenal primary disease).

The NWTS-5 trial closed the arm for patients with rhabdoid tumor who were treated with cyclophosphamide, etoposide, and carboplatin because poor outcomes were observed. Combinations of etoposide and cisplatin; etoposide and ifosfamide; and ifosfamide, carboplatin, and etoposide (ICE chemotherapy) have been used.[26,27]

Sources: NWTS-5 · 26 · 27

No formal trial has yet shown an advantage of higher-dose alkylator therapy (e.g., cyclophosphamide doses of 4.2 g/m2/cycle) or high-dose chemotherapy with stem cell rescue for non-CNS rhabdoid tumors.[28] A retrospective analysis from the Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) group found no benefit using high-dose chemotherapy with stem cell rescue for patients with rhabdoid tumor of the kidney.[29]

Sources: 28 · 29

A retrospective analysis of 58 patients with malignant rhabdoid tumor of the kidney from the International Society of Paediatric Oncology (SIOP), GPOH, and European Rhabdoid Tumor Registry was performed.[29]

Sources: 29

A retrospective analysis of 58 patients with malignant rhabdoid tumor of the kidney from the International Society of Paediatric Oncology (SIOP), GPOH, and European Rhabdoid Tumor Registry was performed.[29]

For the entire group, the 2-year event-free survival (EFS) rate was 37%, and the OS rate was 38%.

Patients with multifocal involvement (n = 12) had significantly inferior survival than did patients with pulmonary or mediastinal metastases or local disease.

Patients who underwent up-front chemotherapy had a lower, but not statistically significant, 2-year EFS rate than did patients who underwent immediate surgical resection.

Younger age (<12 months) and local stage III disease were associated with significantly inferior survival than were stage I and stage II disease.

No difference was seen in 2-year EFS rates for patients without progression within 90 days consolidated by high-dose hematopoietic stem cell transplant (HSCT) (n = 10) compared with patients without consolidation by HSCT (n = 21).

In a separate analysis of the same patient population, investigators examined the role of radiation therapy for local control in patients with higher-stage disease. Twenty-one patients (stages II and III) received radiation therapy during first-line treatment, 18 of whom received radiation therapy to all involved sites. The local failure rate was 29% for patients with local stage II or stage III disease who received radiation therapy to all sites, compared with 68% for nonirradiated patients. The progression-free survival rate was 67% for patients with local stage II and stage III disease who were treated with radiation therapy during first-line treatment (adjusted for early relapse or treatment abandonment), compared with 15% for patients who did not receive radiation therapy (P < .0001).[30][Level of evidence C1]

Sources: 30 · Level of evidence C1

Health professional · Rhabdoid Tumors of the Kidney

Treatment Options Under Clinical Evaluation for Rhabdoid Tumors of the Kidney

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

The following is an example of a national and/or institutional clinical trial that is currently being conducted:

PEPN2121 (NCT05286801) (Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1- or SMARCA4-Deficient Tumors): This study is evaluating the combination of a PD-L1 targeting antibody (atezolizumab) with a TIGIT targeting antibody (tiragolumab) for patients with SMARCB1- or SMARCA4-deficient tumors.

Sources: PEPN2121 (NCT05286801)

Health professional · Clear Cell Sarcoma of the Kidney

Treatment of Clear Cell Sarcoma of the Kidney

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Because of the relative rarity of this tumor, all patients with clear cell sarcoma of the kidney should consider joining a clinical trial. Treatment planning by a multidisciplinary team of pediatric cancer specialists (surgeon or urologist, radiation oncologist, and oncologist) with experience treating renal tumors is required to determine and implement optimal treatment.

The approach for treating clear cell sarcoma of the kidney is different from the approach for treating Wilms tumor because the overall survival (OS) of children with clear cell sarcoma of the kidney remains lower than that for patients with FH Wilms tumor. All patients, except those who have lymph nodes sampled and are stage I, undergo postoperative radiation therapy to the tumor bed and receive doxorubicin as part of their chemotherapy regimen.

The standard treatment option for stage I (must have lymph nodes sampled) clear cell sarcoma of the kidney is the following:

Surgery and chemotherapy.[16]

Sources: 16

The standard treatment option for stages II through IV clear cell sarcoma of the kidney is the following:

Surgery, chemotherapy, and radiation therapy.[16]

Sources: Surgery, chemotherapy, and radiation therapy · 16

Health professional · Clear Cell Sarcoma of the Kidney / Treatment of Clear Cell Sarcoma of the Kidney

Surgery, chemotherapy, and radiation therapy

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Evidence (surgery, chemotherapy, and radiation therapy):

In the AREN0321 (NCT00335556) study, patients (n = 82) with stages I, II, and III disease were treated with regimen I, which consisted of vincristine, doxorubicin, cyclophosphamide, and etoposide. Based on the excellent results of stage I patients in the NWTS-5 study, radiation therapy was omitted for patients with stage I disease who had lymph nodes sampled. Patients with stage IV disease were treated with a carboplatin-containing regimen. There were 50 patients in the AREN03B2 (NCT00898365) study who were treated with the same stage-appropriate therapy. The results from the two studies are as follows:[16]

Sources: AREN0321 (NCT00335556) · AREN03B2 (NCT00898365) · 16

In the AREN0321 (NCT00335556) study, patients (n = 82) with stages I, II, and III disease were treated with regimen I, which consisted of vincristine, doxorubicin, cyclophosphamide, and etoposide. Based on the excellent results of stage I patients in the NWTS-5 study, radiation therapy was omitted for patients with stage I disease who had lymph nodes sampled. Patients with stage IV disease were treated with a carboplatin-containing regimen. There were 50 patients in the AREN03B2 (NCT00898365) study who were treated with the same stage-appropriate therapy. The results from the two studies are as follows:[16]

In the AREN0321 study, the 4-year EFS rate was 82.7%, and the OS rate was 95.1%.

For patients treated in both studies with the same stage-appropriate therapy, the 4-year EFS rates were 90.0% for stage I (n = 10), 93.4% for stage II (n = 47), 82.8% for stage III (n = 65), and 58.3% for stage IV (n = 10) patients. The 4-year OS rates were 100% for stage I, 97.9% for stage II, 93.8% for stage III, and 77.8% for stage IV patients.

No local recurrences were seen in patients with stage I disease who did not receive radiation therapy (n = 7). One patient with stage I disease experienced a brain recurrence.

Among patients with local stage III tumors, initial procedure type, margin status, and lymph node involvement were not prognostic factors.

The brain remains the most common site of relapse (n = 8). Fourteen relapses occurred within 3 years, including ten that occurred within 2 years. The latest relapse occurred at 3.5 years.

Patients with stage IV disease appeared to benefit from the addition of carboplatin.

In the National Wilms Tumor Study (NWTS) NWTS-5 (COG-Q9401/NCT00002611) trial, children with stages I to IV clear cell sarcoma of the kidney were treated with a new chemotherapeutic regimen combining vincristine, doxorubicin, cyclophosphamide, and etoposide in an attempt to further improve the survival of these high-risk groups. All patients received radiation therapy to the tumor bed.[3]

Sources: NWTS-5 (COG-Q9401/NCT00002611) · 3

In the National Wilms Tumor Study (NWTS) NWTS-5 (COG-Q9401/NCT00002611) trial, children with stages I to IV clear cell sarcoma of the kidney were treated with a new chemotherapeutic regimen combining vincristine, doxorubicin, cyclophosphamide, and etoposide in an attempt to further improve the survival of these high-risk groups. All patients received radiation therapy to the tumor bed.[3]

With this treatment, the 5-year EFS rate was 79%, and the OS rate was 90%.

Stage I patients had 5-year EFS and OS rates of 100%.

Stage II patients had a 5-year EFS rate of 88% and a 5-year OS rate of 98%.

Stage III patients had a 5-year EFS rate of 73% and a 5-year OS rate of 89%.

Stage IV patients had a 5-year EFS rate of 29% and a 5-year OS rate of 36%.

A review of patients with stage I clear cell sarcoma of the kidney treated on the NWTS-1, NWTS-2, NWTS-3, NWTS-4, and NWTS-5 trials showed an excellent OS rate of 100% with a wide variety of chemotherapy and radiation therapy regimens.[17]

Sources: NWTS-5 · 17

In the NWTS-3 trial, the addition of doxorubicin to the combination of vincristine, dactinomycin (DD-4A), and radiation therapy resulted in an improvement in disease-free survival for patients with clear cell sarcoma of the kidney.[1] The NWTS-4 trial expanded on this trial, with patients randomly assigned to either 15 months of therapy or 6 months of therapy.[18]

Sources: 1 · 18

In the NWTS-3 trial, the addition of doxorubicin to the combination of vincristine, dactinomycin (DD-4A), and radiation therapy resulted in an improvement in disease-free survival for patients with clear cell sarcoma of the kidney.[1] The NWTS-4 trial expanded on this trial, with patients randomly assigned to either 15 months of therapy or 6 months of therapy.[18]

Patients who were treated with DD-4A for 15 months had an improved relapse-free survival rate compared with patients who were treated for 6 months (88% vs. 61% at 8 years).

Health professional · Clear Cell Sarcoma of the Kidney

Treatment of Recurrent Clear Cell Sarcoma of the Kidney

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Patients with most forms of recurrent childhood cancer should consider enrolling in phase I and phase II clinical trials. Other treatment options for clear cell sarcoma of the kidney are discussed below.

Palliative care remains a central focus of management regardless of whether disease-directed therapy is pursued at the time of progression. This ensures that quality of life is maximized while attempting to reduce symptoms and stress related to the terminal illness.

Clear cell sarcoma of the kidney has been characterized by late relapses. However, in trials after 1992, most relapses occurred within 3 years, and the most common sites of recurrence were the brain and the lungs.[3,5,16] In a series of 37 patients with clear cell sarcoma of the kidney who relapsed, the 5-year EFS rate after relapse was 18%, and the OS rate after relapse was 26%.[5]

Sources: 3 · 5 · 16 · 5

The optimal treatment of relapsed clear cell sarcoma of the kidney has not been established. Treatment of patients with recurrent clear cell sarcoma of the kidney depends on initial therapy and site of recurrence.

Treatment options for recurrent clear cell sarcoma of the kidney include the following:

Chemotherapy, complete surgical resection (if possible), and/or radiation therapy.

Cyclophosphamide and carboplatin should be considered if not used initially. Patients with recurrent clear cell sarcoma of the kidney, in some cases involving the brain, have responded to treatment with ifosfamide, carboplatin, and etoposide (ICE), coupled with local control consisting of surgical resection, radiation therapy, or both.[5]; [4][Level of evidence B4]

Sources: 5 · 4 · Level of evidence B4

The use of high-dose chemotherapy followed by hematopoietic stem cell transplant (HSCT) is undefined in patients with recurrent clear cell sarcoma of the kidney. A total of 24 patients with relapsed clear cell sarcoma of the kidney received high-dose chemotherapy followed by autologous HSCT. Of those patients, 12 (50%) were alive without disease after a median of 52 months. Patients who had already achieved a second complete remission were more likely to receive high-dose chemotherapy.[4,5,19]

Sources: 4 · 5 · 19

Health professional · Clear Cell Sarcoma of the Kidney / Treatment of Recurrent Clear Cell Sarcoma of the Kidney

Treatment options under clinical evaluation for recurrent clear cell sarcoma of the kidney

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Information about NCI-supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

Health professional · Congenital Mesoblastic Nephroma

Treatment of Congenital Mesoblastic Nephroma

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

The OS of patients with congenital mesoblastic nephroma is excellent. However, reported causes of death are treatment related in about one-half of the cases. Additionally, most of these patients were very young (median age, <1 year).[4] This underscores the special attention that infants with renal tumors require, with respect to timing and type of treatment and the importance of a dedicated expert pediatric oncology setting.

Sources: 4

Standard treatment options for stages I and II (80% of patients) and stage III (classic and mixed subtypes) congenital mesoblastic nephroma include the following:

Nephrectomy only (stages I and II all subtypes and stage III classic and mixed subtypes).

Sources: Nephrectomy only

Adjuvant chemotherapy (stage III cellular subtype).

Sources: Adjuvant chemotherapy

Health professional · Congenital Mesoblastic Nephroma / Treatment of Congenital Mesoblastic Nephroma

Nephrectomy

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Evidence (nephrectomy):

A SIOP/Gesellschaft für Pädiatrische Hämatologie und Onkologie (GPOH) nephroblastoma study evaluated 111 patients with congenital mesoblastic nephromas. Sixty-seven patients had classical congenital mesoblastic nephromas (60%), 29 patients had the cellular subtype (26%), and 15 patients had the mixed subtype (14%). Tumor stage consisted of stage I (35%), stage II (50%), and stage III (15%). Ninety-one patients were treated with surgery alone, and 19 patients were treated with chemotherapy in addition to surgery (12 preoperatively and 11 postoperatively).[8]

Sources: 8

A SIOP/Gesellschaft für Pädiatrische Hämatologie und Onkologie (GPOH) nephroblastoma study evaluated 111 patients with congenital mesoblastic nephromas. Sixty-seven patients had classical congenital mesoblastic nephromas (60%), 29 patients had the cellular subtype (26%), and 15 patients had the mixed subtype (14%). Tumor stage consisted of stage I (35%), stage II (50%), and stage III (15%). Ninety-one patients were treated with surgery alone, and 19 patients were treated with chemotherapy in addition to surgery (12 preoperatively and 11 postoperatively).[8]

Overall, the 5-year RFS rate was 93.2%, and the 5-year OS rate was 96.8%

The 5-year RFS rate was significantly superior for the classical type (98%) compared with the cellular type (89%, P = .039) or mixed type (80%, P = .002). There was no significant difference in OS by tumor types.

Seven patients relapsed (five local and two combined) and three patients died because of local relapse (one of each histological type).

Tissue was available for translocation analysis from 79 of the 111 tumors. Within the group of cellular congenital mesoblastic nephromas, patients who had translocation-positive tumors had a significantly improved RFS compared with the patients who had translocation-negative tumors (5-year RFS rate, 100% vs. 73%).

Health professional · Congenital Mesoblastic Nephroma / Treatment of Congenital Mesoblastic Nephroma

Adjuvant chemotherapy

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Adjuvant chemotherapy has been recommended for patients with stage III cellular subtype mesoblastic nephromas who are aged 3 months or older at diagnosis.[5] In a study of stage III cellular type congenital mesoblastic nephroma, 7 of 12 patients who were treated with surgery only suffered from a relapse, while 4 of 14 patients who were treated with adjuvant chemotherapy (primarily dactinomycin/vincristine and sometimes doxorubicin) developed a relapse.[1,5,13] Cyclophosphamide and ifosfamide have been combined with these agents and have shown activity.[14]

Sources: 5 · 1 · 5 · 13 · 14

Infants younger than 2 months with incompletely resected, stage III disease may not need chemotherapy.[1]

Sources: 1

Health professional · Congenital Mesoblastic Nephroma

Treatment Options Under Clinical Evaluation for Congenital Mesoblastic Nephroma

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

Health professional · Congenital Mesoblastic Nephroma

Treatment of Recurrent Congenital Mesoblastic Nephroma

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Patients with most forms of recurrent childhood cancer should consider enrolling in phase I and phase II clinical trials. Other treatment options for recurrent congenital mesoblastic nephroma are discussed below.

Palliative care remains a central focus of management regardless of whether disease-directed therapy is pursued at the time of progression. This ensures that quality of life is maximized while attempting to reduce symptoms and stress related to the terminal illness.

Relapses were reported in 4% of patients with congenital mesoblastic nephroma, and all relapses occurred within 12 months after diagnosis. Most relapses occurred locally, although metastatic relapses have been reported.[4] About 70% of patients who relapsed survived with individualized treatment comprising combinations of surgery, chemotherapy, and radiation therapy.[4]

Sources: 4 · 4

Targeted therapy should be considered for patients with recurrent or refractory disease containing the ETV6::NTRK3 fusion. Larotrectinib and entrectinib are NTRK inhibitors that are approved for adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance variant, who are either metastatic or when surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or whose cancer has progressed after treatment.[15,16]

Sources: 15 · 16

Health professional · Congenital Mesoblastic Nephroma / Treatment of Recurrent Congenital Mesoblastic Nephroma

Treatment options under clinical evaluation for recurrent congenital mesoblastic nephroma

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Information about NCI-supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

Health professional · Ewing Sarcoma of the Kidney

Treatment of Ewing Sarcoma of the Kidney

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

There is no consensus for the optimal treatment of Ewing sarcoma of the kidney because data are lacking. The current treatment approach is extrapolated from the experience of treating Ewing sarcoma at other sites with multimodal therapy consisting of multiagent chemotherapy, surgery, and/or radiation therapy for local control. The MD Anderson Cancer Center reported their experience with 30 patients (median age, 30.5 years) with Ewing sarcoma of the kidney over a period of 23 years.[5]

Sources: 5

Twenty percent of the patients had tumors confined to the kidney, 23% had tumors extending locally beyond the kidney, and 57% had metastasis at diagnosis (lungs, liver, and bone). The 4-year EFS and OS rates were 54% and 85%, respectively, for patients without metastasis at diagnosis, compared with 35% and 47%, respectively, for patients with metastasis.

Patients with tumors confined to the kidney and treated with nephrectomy and adjuvant chemotherapy have favorable outcomes compared with patients who did not complete adjuvant therapy. Twelve of 13 patients with nonmetastatic disease who underwent upfront nephrectomy had a favorable outcome when adjuvant chemotherapy was used.

Presence of tumor thrombus in the renal vein and/or inferior vena cave was associated with worse EFS (P = .053).

Unfavorable prognostic factors were local tumor extension beyond the kidney, tumor thrombus, and distant metastasis.

The most commonly used chemotherapy was vincristine, cyclophosphamide, doxorubicin, ifosfamide, etoposide, cisplatin, irinotecan, and temozolomide. The most common initial chemotherapy used was vincristine, doxorubicin, and cyclophosphamide, either alone (23%) or in combination with ifosfamide and etoposide (23%). The second most common combination used was vincristine, doxorubicin, and ifosfamide.

Treatment according to Ewing sarcoma protocols should be considered.[1]

Sources: 1

For more information, see Ewing Sarcoma and Undifferentiated Small Round Cell Sarcomas of Bone and Soft Tissue Treatment.

Sources: Ewing Sarcoma and Undifferentiated Small Round Cell Sarcomas of Bone and Soft Tissue Treatment

Health professional · Primary Renal Myoepithelial Carcinoma

Treatment of Primary Renal Myoepithelial Carcinoma

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Although no standard therapy has been established, surgical resection of the primary tumor and pulmonary nodules (if present) has been used in addition to chemotherapy and radiation therapy.[2]

Sources: 2

Health professional · Cystic Partially Differentiated Nephroblastoma

Treatment of Cystic Partially Differentiated Nephroblastoma

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Surgery is the main treatment. Preoperative chemotherapy administration was reported in 20 of 98 patients. None of the preoperatively treated patients showed response to chemotherapy on imaging or histological examination.[1]

Sources: 1

Standard treatment options for cystic partially differentiated nephroblastoma include the following:

Surgery. Patients with stage I disease have a 100% survival rate with surgery alone.[4]

Sources: 4

Surgery and adjuvant chemotherapy. Patients with stage II disease have an excellent outcome with tumor resection followed by postoperative vincristine and dactinomycin.[4]

Sources: 4

Health professional · Multilocular Cystic Nephroma

Treatment of Multilocular Cystic Nephroma

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

The standard treatment option for multilocular cystic nephroma is surgery.

Health professional · Anaplastic Sarcoma of the Kidney

Treatment of Anaplastic Sarcoma of the Kidney

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

There is no standard treatment option for anaplastic sarcoma of the kidney.

In a series of 40 patients with anaplastic sarcoma of the kidney who had staging data available, 13 had stage I disease, 12 had stage II disease, 10 had stage III disease, and 5 had stage IV disease.[1]

Sources: 1

Most patients (38 of 46) received up-front chemotherapy, and 14 patients received up-front radiation therapy. The 2-year event-free survival (EFS) rate was 81.8% for patients with stage I and stage II disease, compared with 46.6% for patients with stage III and stage IV disease (P = .07). The 2-year overall survival (OS) rate was 88.9% for patients with stage I and stage II disease, compared with 70.0% for patients with stage III and stage IV disease (P = .20).

Chemotherapy was associated with improved EFS and OS (hazard ratios [HRs], 0.09 and 0.08, respectively).

Patients (including those with stage I and stage II disease) treated with chemotherapy and surgery had lower risks of recurrence than those who had surgery alone.

The most common treatment protocols are based on Ewing sarcoma– and anaplastic Wilms tumor–directed therapies. These protocols use combinations of vincristine, doxorubicin, cyclophosphamide, and etoposide with or without ifosfamide, dactinomycin, and carboplatin.

Up-front radiation therapy was used in 14 patients. Only two recurrences were reported.

Older age at diagnosis was associated with worse outcomes (EFS HR, 1.08; OS HR, 1.07). Age groups of 0 to 3 years and 4 to 9 years had similar 2-year EFS rates (80% and 84.6%, respectively) and OS rates (100% and 92.3%, respectively). Patients older than 9 years had lower 2-year EFS rates (54.2%) and OS rates (68.4%) (EFS, P < .01; OS, P = .07).

In the posttherapy setting, surveillance for PPB, thyroid tumors, and/or ovarian tumors should be considered. Surveillance strategies will depend on which germline DICER1 pathogenic variant is detected and whether mosaicism is present.[1,11]

Sources: 1 · 11

Health professional · Primary Renal Synovial Sarcoma

Treatment of Primary Renal Synovial Sarcoma

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Although no standard treatment guidelines exist, surgery is considered the treatment of choice. Chemotherapy (ifosfamide with doxorubicin or epirubicin) has been used in about 31% of cases in the adjuvant setting.[1] The chemotherapy regimens used differ from those traditionally used for Wilms tumor.[3]

Sources: 1 · 3

Health professional · Nephroblastomatosis

Treatment of Nephroblastomatosis (Diffuse Hyperplastic Perilobar Nephroblastomatosis)

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Left untreated, all patients with diffuse hyperplastic perilobar nephroblastomatosis have been reported to develop Wilms tumors.[1,2] Although most cases of diffuse hyperplastic perilobar nephroblastomatosis are bilateral, a few cases have been reported with unilateral occurrence.[1] Until recently, diffuse hyperplastic perilobar nephroblastomatosis had not been prospectively studied by any of the pediatric oncology groups. As a result, patients have been treated in a variety of ways (observation, multiple chemotherapeutic agents in a nonstandard manner, or flank radiation therapy).[2] Additionally, a consistent definition of diffuse hyperplastic perilobar nephroblastomatosis has not been uniformly applied to all cases.

Sources: 1 · 2 · 1 · 2

Treatment options for diffuse hyperplastic perilobar nephroblastomatosis include the following:

Preoperative chemotherapy.[3]

Sources: 3

Renal-sparing surgery. Given the high incidence of bilaterality and subsequent Wilms tumors, renal-sparing surgery may be indicated.[1]

Sources: 1

Evidence (preoperative chemotherapy and surgery):

The Children’s Oncology Group AREN0534 (NCT00945009) study was the first clinical trial to prospectively enroll and uniformly treat patients with diffuse hyperplastic perilobar nephroblastomatosis. Patients were enrolled after having central radiological review. Diffuse hyperplastic perilobar nephroblastomatosis was defined as the cortical surface of the kidney being composed of hyperplastic rests, with the entire nephrogenic zone involved, and with a thick rind capping all of one or both kidneys. Patients were treated with induction chemotherapy consisting of vincristine and dactinomycin (regimen EE-4A) and had cross-sectional imaging at weeks 6 and 12. Therapy could be continued if the patient's disease was stable or decreasing. Maximum treatment duration was 19 weeks.[3][Level of evidence: C1]

Sources: AREN0534 (NCT00945009) · 3 · Level of evidence: C1

The Children’s Oncology Group AREN0534 (NCT00945009) study was the first clinical trial to prospectively enroll and uniformly treat patients with diffuse hyperplastic perilobar nephroblastomatosis. Patients were enrolled after having central radiological review. Diffuse hyperplastic perilobar nephroblastomatosis was defined as the cortical surface of the kidney being composed of hyperplastic rests, with the entire nephrogenic zone involved, and with a thick rind capping all of one or both kidneys. Patients were treated with induction chemotherapy consisting of vincristine and dactinomycin (regimen EE-4A) and had cross-sectional imaging at weeks 6 and 12. Therapy could be continued if the patient's disease was stable or decreasing. Maximum treatment duration was 19 weeks.[3][Level of evidence: C1]

Nine patients were enrolled, and the median age was 10 months. One patient was not evaluable based on radiological criteria for diffuse hyperplastic perilobar nephroblastomatosis. Eight patients had confirmed bilateral diffuse hyperplastic perilobar nephroblastomatosis and started chemotherapy without tissue diagnosis. One patient had an upfront partial nephrectomy that was found to have diffuse hyperplastic perilobar nephroblastomatosis in the specimen and was subsequently treated with EE-4A. All patients were alive at a median follow-up of 6.6 years (range, 4.5–9.1 years).

No patients were anephric. Fourteen of the 16 kidneys were functioning (87.5%).

Three of eight patients did not develop Wilms tumor. One of these patients had a complete radiographic response, one had a few sclerotic lesions at the end of therapy, and one had significant response but still had radiographic abnormalities.

Five of eight patients had Wilms tumor at some point in their disease: one at diagnosis, one during therapy, and three after therapy (at 2 months and again at 4 months, 6 months, and 8 months). Only one of the patients developed a Wilms tumor with anaplastic histology.

A 19-week course of EE-4A prevents some patients from developing Wilms tumor (three of eight), but it is not fully effective. The ideal duration of therapy remains unknown.

In a retrospective series of 52 patients with diffuse hyperplastic perilobar nephroblastomatosis (46 with confirmed diffuse hyperplastic perilobar nephroblastomatosis), 33 patients were treated with chemotherapy and/or radiation therapy initially, 16 patients underwent unilateral nephrectomy followed by adjuvant therapy, and 3 patients were observed only.[1]

Sources: 1

In a retrospective series of 52 patients with diffuse hyperplastic perilobar nephroblastomatosis (46 with confirmed diffuse hyperplastic perilobar nephroblastomatosis), 33 patients were treated with chemotherapy and/or radiation therapy initially, 16 patients underwent unilateral nephrectomy followed by adjuvant therapy, and 3 patients were observed only.[1]

A total of 24 patients developed Wilms tumor (including the 3 patients who were observed only), at a median of 30 months.

Eighteen of the 33 patients who received chemotherapy alone developed a Wilms tumor.

Of 16 patients who underwent a nephrectomy and adjuvant therapy, 3 developed Wilms tumor, despite the fact that 14 of 16 patients had bilateral disease.

Thirty-three percent of the patients who developed Wilms tumor had anaplastic Wilms tumor at some time during their course, probably as a result of selection of chemotherapy-resistant tumors; thus, early detection is critical.

Health professional

Special Considerations for the Treatment of Children With Cancer

Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025. Captured 2026-09-09.

Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:

Sources: 1

Primary care physicians.

Pediatric surgeons.

Transplant surgeons.

Pathologists.

Pediatric radiation oncologists.

Pediatric medical oncologists and hematologists.

Ophthalmologists.

Rehabilitation specialists.

Pediatric oncology nurses.

Social workers.

Child-life professionals.

Psychologists.

Nutritionists.

For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.

Sources: Supportive and Palliative Care

The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.

Sources: 2 · NCI website

For patients · Types of kidney cancer in children / Renal cell cancer (RCC)

Treatment of RCC

Source: Kidney Cancer in Children (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Treatment of renal cell cancer may include:

surgery, which may be either nephrectomy or partial nephrectomy with removal of lymph nodes

Sources: nephrectomy

immunotherapy, such as interleukin-2, for cancer that has spread to other parts of the body

Sources: immunotherapy · interleukin-2

targeted therapy, such as sunitinib or cabozantinib, for cancer that has spread to other parts of the body

Sources: targeted therapy · sunitinib · cabozantinib

Learn more about these treatments in the Types of treatment section.

Sources: Types of treatment

If the cancer comes back after treatment, your child's doctor will talk with you about what to expect and next steps. There might be treatment options that shrink the cancer or control its growth. If there are no treatment options, your child can receive care to control their cancer symptoms so they can be as comfortable as possible.

For patients · Types of kidney cancer in children / Rhabdoid tumor of the kidney

Treatment of rhabdoid tumor of the kidney

Source: Kidney Cancer in Children (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

There is no standard treatment for rhabdoid tumor of the kidney. Treatment may include:

Sources: standard treatment

a combination of surgery, chemotherapy, or radiation therapy

high-dose chemotherapy with or without stem cell transplant

Sources: stem cell transplant

Learn more about these treatments in the Types of treatment section.

Sources: Types of treatment

If the cancer comes back after treatment, your child's doctor will talk with you about what to expect and possible next steps. There might be treatment options that may shrink the cancer or control its growth. If there are no treatments, your child can receive care to control symptoms from cancer so they can be as comfortable as possible.

For patients

Types of treatment for kidney cancer in children

Source: Kidney Cancer in Children (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

For patients · Types of treatment for kidney cancer in children

Who treats children with kidney cancer?

Source: Kidney Cancer in Children (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

A pediatric oncologist, a doctor who specializes in treating children with cancer, oversees treatment of kidney cancer. The pediatric oncologist works with other health care providers who are experts in treating children with childhood kidney tumors and also specialize in other areas of medicine. Other specialists may include:

pediatrician

Sources: pediatrician

pediatric surgeon or urologist

Sources: pediatric surgeon · urologist

radiation oncologist

Sources: radiation oncologist

pathologist

Sources: pathologist

pediatric nurse specialist

Sources: pediatric nurse specialist

social worker

Sources: social worker

rehabilitation specialist

Sources: rehabilitation specialist

psychologist

Sources: psychologist

child-life specialist

Sources: child-life specialist

fertility specialist

Sources: fertility specialist

For patients · Types of treatment for kidney cancer in children

Treatment options

Source: Kidney Cancer in Children (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

There are different types of treatment for children and adolescents with kidney cancer. You and your child’s cancer team will work together to decide treatment. Treatment will depend on factors such as your child’s overall health and whether the cancer is newly diagnosed or has come back.

Your child’s treatment plan will include information about the cancer, the goals for treatment, treatment options, and the possible side effects. It will be helpful to talk with your child’s cancer care team before treatment begins about what to expect. For help every step of the way, visit our booklet, Children with Cancer: A Guide for Parents.

Sources: Children with Cancer: A Guide for Parents

Types of treatment your child might have include:

For patients · Types of treatment for kidney cancer in children / Treatment options

Surgery

Source: Kidney Cancer in Children (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Children with kidney cancer may have surgery to obtain a biopsy sample or to remove the cancer. There are two types of surgery used to treat kidney cancer:

Nephrectomy is surgery to remove the whole kidney. This surgery is the most common treatment for kidney cancer. Nearby lymph nodes may also be removed and checked for cancer. If the cancer is in both kidneys and they are not working well, your child may have a kidney transplant. A transplant is surgery to remove a kidney and replace it with one from a donor.

Sources: donor

Partial nephrectomy is the removal of the cancer in the kidney and a small amount of normal tissue around it. Your child may have this surgery if cancer is found in both kidneys or is likely to spread to both kidneys. The goal of the surgery is to keep as much of the kidney as possible. A partial nephrectomy is also called renal-sparing surgery.

After the doctor removes all the cancer that can be seen at the time of the surgery, your child may have chemotherapy, radiation therapy, or both to kill any cancer cells that are left. Sometimes after chemotherapy or radiation therapy, doctors will do a second-look surgery to see if cancer remains.

Sources: second-look surgery

Sometimes kidney cancer cannot be removed for one of these reasons:

the tumor is too close to important organs or blood vessels

the tumor is too large to remove

the cancer is in both kidneys, unless the tumors are very small

there is a blood clot in the vessels near the liver

Sources: blood clot

your child has trouble breathing because cancer has spread to the lungs

In this case, your child will have a biopsy first. Then they will receive chemotherapy to reduce the size of the tumor before surgery. The goal of this approach is to save as much healthy tissue as possible and reduce problems after surgery.

For patients · Types of treatment for kidney cancer in children / Treatment options

Radiation therapy

Source: Kidney Cancer in Children (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. A type of radiation therapy called external beam radiation is used to treat childhood kidney tumors. It uses a machine outside the body to send radiation toward the area of the body with cancer. Radiation therapy may be given alone or with other treatments, such as chemotherapy.

To learn more, visit External Beam Radiation Therapy for Cancer and Radiation Therapy Side Effects.

Sources: External Beam Radiation Therapy for Cancer · Radiation Therapy Side Effects

For patients · Types of treatment for kidney cancer in children / Treatment options

Chemotherapy

Source: Kidney Cancer in Children (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Chemotherapy (also called chemo) uses drugs to kill cancer cells or stop them from dividing. Chemotherapy may be given alone or with other types of treatment, such as radiation therapy.

For children with kidney cancer, chemotherapy is taken by mouth or injected into a vein. When given this way, chemotherapy enters the bloodstream and can reach cancer cells throughout the body. Chemotherapy that is used alone or in combination to treat kidney cancer include:

carboplatin

Sources: carboplatin

cisplatin

Sources: cisplatin

cyclophosphamide

Sources: cyclophosphamide

dactinomycin

Sources: dactinomycin

doxorubicin

Sources: doxorubicin

etoposide

Sources: etoposide

ifosfamide

Sources: ifosfamide

irinotecan

Sources: irinotecan

temozolomide

Sources: temozolomide

vincristine

Sources: vincristine

Other chemotherapy not listed here may also be used.

Sometimes chemotherapy is given before surgery to reduce the size of the tumor. Shrinking the tumor before surgery can help save as much healthy tissue as possible and reduce problems after surgery. This is called neoadjuvant chemotherapy.

Learn more about how chemotherapy works, how it is given, common side effects, and more at Chemotherapy to Treat Cancer.

Sources: Chemotherapy to Treat Cancer

For patients · Types of treatment for kidney cancer in children / Treatment options

Immunotherapy

Source: Kidney Cancer in Children (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Immunotherapy uses your child’s immune system to fight cancer. Immunotherapy that may be used to treat kidney cancer in children includes interleukin-2 (IL-2).

Sources: immune system · interleukin-2

To learn more about immunotherapy, visit Immunotherapy to Treat Cancer.

Sources: Immunotherapy to Treat Cancer

For patients · Types of treatment for kidney cancer in children / Treatment options

Stem cell transplant

Source: Kidney Cancer in Children (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Stem cell transplant (stem cell rescue) is a procedure to replace the blood-forming stem cells that are destroyed when high doses of chemotherapy are given to kill cancer cells. Before high-dose chemotherapy, stem cells (immature blood cells) are removed from the blood or bone marrow of your child and stored in a freezer. After your child completes chemotherapy, the frozen stem cells are thawed and given back to them through an infusion. These stem cells grow into new blood cells.

Sources: bone marrow · infusion

For patients · Types of treatment for kidney cancer in children / Treatment options

Targeted therapy

Source: Kidney Cancer in Children (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Targeted therapy uses drugs or other substances to identify and attack specific cancer cells. Targeted therapy that is used or being studied to treat childhood kidney cancer may include:

cabozantinib

Sources: cabozantinib

entrectinib

Sources: entrectinib

larotrectinib

Sources: larotrectinib

sunitinib

Sources: sunitinib

To learn more, visit Targeted Therapy to Treat Cancer.

Sources: Targeted Therapy to Treat Cancer

For patients · Types of treatment for kidney cancer in children / Treatment options

Clinical trials

Source: Kidney Cancer in Children (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

For some children, joining a clinical trial may be an option. There are different types of clinical trials for childhood cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.

You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your child's age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trial search · ClinicalTrials.gov

Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.

Sources: Clinical Trials Information for Patients and Caregivers

For patients

Side effects and late effects of treatment

Source: Kidney Cancer in Children (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Cancer treatments can cause side effects. Which side effects your child has depends on the type of treatment they receive, the dose, and how their body reacts. Talk with your child's treatment team about which side effects to look for and ways to manage them.

To learn more about side effects that begin during treatment for cancer, visit Side Effects.

Sources: side effects · Side Effects

Problems from cancer treatment that begin 6 months or later after treatment and continue for months or years are called late effects. Late effects of cancer treatment may include:

physical problems, such as trouble with exercise, mobility, strength, and flexibility

chronic health conditions that could affect the heart, lungs, kidneys, intestines, and hormone levels

infertility or problems during pregnancy including high blood pressure, early labor, or the baby being in an unusual position as birth approaches

Sources: infertility · pregnancy

neurological symptoms, such as changes in mood, feelings, thinking, learning, or memory

second cancers (new types of cancer), such as leukemias, thyroid cancer, cancer of the gastrointestinal tract, breast cancer, or skin cancer

Sources: leukemias · thyroid cancer · gastrointestinal tract · breast cancer · skin cancer

Some late effects may be treated or controlled. It is important to talk with your child's doctors about the effects cancer treatment can have on your child. Learn more about Late Effects of Treatment for Childhood Cancer.

Sources: Late Effects of Treatment for Childhood Cancer

For patients

Types of treatment for Wilms tumor

Source: Wilms Tumor (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

For patients · Types of treatment for Wilms tumor

Who treats children with Wilms tumor?

Source: Wilms Tumor (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

A pediatric oncologist, a doctor who specializes in treating children with cancer, oversees treatment of Wilms tumor. The pediatric oncologist works with other health care providers who are experts in treating children and specialize in certain areas of medicine. Other specialists may include:

pediatrician

Sources: pediatrician

pediatric surgeon or urologist

Sources: pediatric surgeon · urologist

radiation oncologist

Sources: radiation oncologist

pathologist

Sources: pathologist

pediatric nurse specialist

Sources: pediatric nurse specialist

social worker

Sources: social worker

rehabilitation specialist

Sources: rehabilitation specialist

psychologist

Sources: psychologist

child-life specialist

Sources: child-life specialist

fertility specialist

Sources: fertility specialist

For patients · Types of treatment for Wilms tumor

Treatment options

Source: Wilms Tumor (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

There are different types of treatment for children and adolescents with Wilms tumor. You and your child's care team will work together to decide treatment. Many factors will be considered, such as:

your child's overall health

the stage of your child's tumor

the histology (favorable or anaplastic)

the risk of cancer coming back after treatment

whether the cancer has spread to other areas in the body

whether both kidneys have cancer

whether your child has an inherited cancer syndrome

whether the cancer is newly diagnosed or has come back

The goal of treatment is to kill the cancer cells and decrease the risk of late effects from treatment.

Your child's treatment plan will include information about the cancer, the goals of treatment, treatment options, and possible side effects. It will be helpful to talk with your child's care team before treatment begins about what to expect. For help every step of the way, visit our booklet, Children with Cancer: A Guide for Parents.

Sources: Children with Cancer: A Guide for Parents

Types of treatment your child might have include:

For patients · Types of treatment for Wilms tumor / Treatment options

Surgery

Source: Wilms Tumor (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Children with Wilms tumor may have surgery to obtain a biopsy sample or to remove the cancer. There are two types of surgery used to treat Wilms tumors:

Nephrectomy is surgery to remove the whole kidney. This is the most common treatment for Wilms tumor. Nearby lymph nodes may also be removed and checked for cancer. If the cancer is in both kidneys and they are not working well, your child may need a kidney transplant. A transplant is surgery to remove the kidney and replace it with one from a donor.

Sources: Nephrectomy · transplant · donor

Partial nephrectomy is the removal of the cancer in the kidney and a small amount of normal tissue around it. Your child may have this surgery if cancer is found in both kidneys or if it is likely to spread to both kidneys. The goal of the surgery is to keep as much of the kidney as possible. A partial nephrectomy is also called renal-sparing surgery.

Sources: Partial nephrectomy

After the doctor removes all the cancer that can be seen at the time of the surgery, your child may have chemotherapy or radiation therapy to kill any cancer cells that are left.

Sometimes, the tumor cannot be removed because:

the tumor is too close to important organs or blood vessels or is growing in important blood vessels (such as the inferior vena cava)

Sources: inferior vena cava

the tumor is too large to remove

the cancer is in both kidneys, unless the tumors are very small

there is a blood clot in the vessels near the liver

Sources: blood clot

the cancer has spread to the lungs, and your child has trouble breathing

If the tumor cannot be removed, your child will have a biopsy first. Then, they will receive chemotherapy to reduce the size of the tumor to make surgery possible. The goal of this approach is to save as much healthy kidney tissue as possible and reduce problems after surgery. Chemotherapy given before surgery is called neoadjuvant chemotherapy.

Sources: biopsy · neoadjuvant

For patients · Types of treatment for Wilms tumor / Treatment options

Radiation therapy

Source: Wilms Tumor (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. Wilms tumor is treated with external beam radiation therapy. This type of therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Radiation therapy may be given alone or with other treatments, such as chemotherapy.

Learn more about External Beam Radiation Therapy for Cancer and Radiation Therapy Side Effects.

Sources: External Beam Radiation Therapy for Cancer · Radiation Therapy Side Effects

For patients · Types of treatment for Wilms tumor / Treatment options

Chemotherapy

Source: Wilms Tumor (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells. Chemotherapy either kills the cells or stops them from dividing. Chemotherapy may be given alone or with other types of treatment, such as radiation therapy.

For children with Wilms tumor, chemotherapy is injected into a vein. When given this way, chemotherapy enters the bloodstream and can reach cancer cells throughout the body.

Chemotherapy drugs used alone or in combination to treat Wilms tumor include:

carboplatin

Sources: carboplatin

cyclophosphamide

Sources: cyclophosphamide

dactinomycin

Sources: dactinomycin

doxorubicin

Sources: doxorubicin

etoposide

Sources: etoposide

ifosfamide

Sources: ifosfamide

irinotecan

Sources: irinotecan

vincristine

Sources: vincristine

Other chemotherapy not listed here may also be used.

Chemotherapy may be given before or after surgery. Chemotherapy given after surgery to kill any cancer cells that remain is called adjuvant therapy.

Sources: adjuvant therapy

Learn more about how chemotherapy works, how it is given, common side effects, and more at Chemotherapy to Treat Cancer.

Sources: Chemotherapy to Treat Cancer

For patients · Types of treatment for Wilms tumor / Treatment options

Stem cell transplant

Source: Wilms Tumor (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Stem cell transplant (or stem cell rescue) is a procedure to replace the blood-forming stem cells that are destroyed when high doses of chemotherapy are given to kill cancer cells. Before high-dose chemotherapy, stem cells (immature blood cells) are removed from the blood or bone marrow of your child and are stored in a freezer. After your child completes chemotherapy, the frozen stem cells are thawed and given back to them through an infusion. These stem cells grow into new blood cells.

Sources: Stem cell transplant · bone marrow · infusion

For patients · Types of treatment for Wilms tumor / Treatment options

Clinical trials

Source: Wilms Tumor (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

For some children, joining a clinical trial may be an option. There are different types of clinical trials for childhood cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.

You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your child's age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trial search · ClinicalTrials.gov

Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.

Sources: Clinical Trials Information for Patients and Caregivers

Clinical trials have led to improvements in the treatment of Wilms tumor, including the number of children who are cured.

For patients

Treatment of Wilms tumor by stage and histology

Source: Wilms Tumor (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

To learn more about the treatments listed below, visit Types of treatment for Wilms tumor.

Sources: Types of treatment for Wilms tumor

For patients · Treatment of Wilms tumor by stage and histology

Stage I Wilms tumor

Source: Wilms Tumor (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Treatment of stage I Wilms tumor with favorable histology may include:

Sources: stage I Wilms tumor · histology

nephrectomy with removal of lymph nodes, followed by combination chemotherapy

Sources: nephrectomy

nephrectomy with removal of lymph nodes for children younger than 2 years and who have a certain weight

Treatment of stage I anaplastic Wilms tumor is nephrectomy with removal of lymph nodes, followed by combination chemotherapy and radiation therapy to the flank area (either side of the body between the ribs and hipbone).

Sources: anaplastic

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Treatment of Wilms tumor by stage and histology

Stage II Wilms tumor

Source: Wilms Tumor (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 12, 2025. Captured 2026-09-09.

Treatment of stage II Wilms tumor with favorable histology is nephrectomy with removal of lymph nodes, followed by combination chemotherapy.

Sources: stage II Wilms tumor · histology

Treatment of stage II anaplastic Wilms tumor is nephrectomy with removal of lymph nodes, followed by radiation therapy to the abdomen and combination chemotherapy.

Sources: anaplastic

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information